<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAB</journal-id>
<journal-id journal-id-type="hwp">sptab</journal-id>
<journal-title>Therapeutic Advances in Musculoskeletal Disease</journal-title>
<issn pub-type="ppub">1759-720X</issn>
<issn pub-type="epub">1759-7218</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1759720X13480280</article-id>
<article-id pub-id-type="publisher-id">10.1177_1759720X13480280</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Latest advances in connective tissue disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Rao</surname><given-names>Vijay</given-names></name>
<aff id="aff1-1759720X13480280">Rheumatology Department, Queen Elizabeth Hospital Birmingham, Birmingham, UK</aff>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bowman</surname><given-names>Simon</given-names></name>
<aff id="aff2-1759720X13480280">Rheumatology Department, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham B15 2TH, UK</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1759720X13480280"><email>simon.bowman@uhb.nhs.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>5</volume>
<issue>4</issue>
<fpage>234</fpage>
<lpage>249</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The connective tissue disorders comprise a number of related conditions that include systemic lupus erythematosus (SLE) and the antiphospholipid (Hughes) syndrome, scleroderma, myositis and Sjögren’s syndrome. They are characterized by autoantibody production and other immune-mediated dysfunction. There are common clinical and serological features with some patients having multiple overlapping connective tissue disorders. The latest advances include new approaches to therapy, including more focused utilization of existing therapies and the introduction of biological therapies in SLE, more precise protocols for assessment of severe disease manifestations such as in interstitial lung disease and pulmonary artery hypertension in scleroderma, new antibodies for disease characterization in myositis and new approaches to patient assessment in Sjögren’s syndrome. B cells have a critical role in most, if not all of these disorders such that B-cell depletion or suppression of B-cell activating cytokines improves disease in many patients. In particular, the introduction of rituximab, a monoclonal antibody targeting the CD20 molecule on B cells, into clinical practice for rheumatoid arthritis and B-cell lymphoma has been a key driver of experimental approaches to therapy in connective tissue disorders. Genetic studies also suggest a role for the innate immune system in disease pathogenesis, suggesting further future targets for biological therapies over the next few years.</p>
</abstract>
<kwd-group>
<kwd>new therapies in connective tissue disorders</kwd>
<kwd>Myositis specific antibodies</kwd>
<kwd>Systemic Lupus Erythematosus</kwd>
<kwd>antiphospholipid antibody syndrome</kwd>
<kwd>Myositis</kwd>
<kwd>scleroderma</kwd>
<kwd>Sjogren’s syndrome</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1759720X13480280">
<title>Systemic lupus erythematosus</title>
<p>Systemic lupus erythematosus (SLE) typically affects women (circa 9:1 female:male ratio) in the 16–55 age group [<xref ref-type="bibr" rid="bibr5-1759720X13480280">Ballou <italic>et al</italic>. 1982</xref>]. It is commoner among patients of African/Afro-Caribbean, South Asian or Chinese/other Asian ethnic groups. It ranges from a mild to a life-threatening or fatal disorder [<xref ref-type="bibr" rid="bibr104-1759720X13480280">Petri <italic>et al.</italic> 2012a</xref>]. Active disease is associated with raised anti-dsDNA antibodies and reduced levels of complement C3 and/or C4 levels. Current therapy is, in fact, very effective for most patients. In mild to moderate disease, hydroxychloroquine is now commonly used as steroid-sparing therapy for all patients. For patients with active disease, corticosteroids are at the heart of current therapy, often combined with steroid sparing agents such as azathioprine, methotrexate, leflunomide, ciclosporin or mycophenolate. In patients with severe or life-threatening renal, nervous system or pulmonary disease, oral or pulsed intravenous cyclophosphamide has been typically used over the past 20 years [<xref ref-type="bibr" rid="bibr16-1759720X13480280">Boumpas <italic>et al.</italic> 1992</xref>]. As a consequence, the survival rate for SLE has steadily increased. In a review of this topic [<xref ref-type="bibr" rid="bibr136-1759720X13480280">Urowitz <italic>et al.</italic> 2008</xref>] the authors point out that since the 1950s, SLE has changed from a disease with a 50% mortality at 5 years to one of over 90% 5-year survival.</p>
<p>The challenge, in recent years, has been less about finding drugs with greater efficacy than corticosteroids and cyclophosphamide and more about developing drug regimes with lower toxicity. Corticosteroids, in particular, have been associated with higher rates of infection, cardiovascular and bone disease [<xref ref-type="bibr" rid="bibr113-1759720X13480280">Ruiz-Irastorza <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr105-1759720X13480280">Petri <italic>et al</italic> 2012b</xref>]. Cyclophosphamide is associated with increased infection risk and with infertility [<xref ref-type="bibr" rid="bibr59-1759720X13480280">Hickman and Gordon, 2011</xref>].</p>
<p>This challenge is now being met following a series of clinical trials over the past few years exploring corticosteroid/cyclophosphamide sparing agents to treat SLE, especially the more severe forms of SLE such as lupus nephritis.</p>
<sec id="section2-1759720X13480280">
<title>Mycophenolate mofetil</title>
<p>The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) in collaboration with the European Renal Association–European Dialysis and Transplant Association have recently brought out guidelines for the management of lupus nephritis [<xref ref-type="bibr" rid="bibr56-1759720X13480280">Hahn <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr12-1759720X13480280">Bertsias <italic>et al</italic>. 2012</xref>]. Both guidelines use renal biopsy as a starting point for therapeutic regimens that include either mycophenolate or ‘low-dose’ cyclophosphamide regimes. These guidelines are broadly similar. To summarize, in patients with mild renal disease (class I) and in patients with advanced kidney damage without significant inflammation (class VI), immunosuppression is not generally indicated. In class II disease with proteinuria (mesangioproliferative lupus nephritis) the EULAR guidelines are more inclined to recommend therapy (low to moderate dose glucocorticoids with or without azathioprine) than the ACR guidelines. In class III–IV lupus nephritis (focal or diffuse inflammation with proliferation), or class V (membranous nephritis) a study of 370 patients by the Aspreva Lupus Management Study Group demonstrated equivalent efficacy of mycophenolate mofetil (MMF) 3 g/day compared with intravenous cyclophosphamide (monthly pulses of 0.5–1 g/m<sup>2</sup>) for 6 months [<xref ref-type="bibr" rid="bibr4-1759720X13480280">Appel <italic>et al.</italic> 2009</xref>]. Tapered doses of prednisolone were used in both arms of the study. The Euro-Lupus Nephritis Trial group demonstrated that, in general, shorter courses of lower dose cyclophosphamide given more frequently (e.g. 500 mg intravenously every 2 weeks for a total of six doses) are as effective as traditional ‘high-dose’ (500—1000 mg/m<sup>2</sup> monthly for 6 months) National Institutes of Health regimes [<xref ref-type="bibr" rid="bibr61-1759720X13480280">Houssiau <italic>et al.</italic> 2002</xref>]. The ACR guidelines suggest that lower doses of MMF may be required in Asian patients and that African-American and Hispanic patients may respond less well to cyclophosphamide than other groups.</p>
<p>Patients whose condition fails to respond to the initial regime can be tried with the alternative (MMF in those who have failed to respond to cyclophosphamide and vice versa). In refractory patients, rituximab, ciclosporin, tacrolimus or other therapies can be considered. For maintenance, either mycophenolate or azathioprine are recommended as preferred therapies [<xref ref-type="bibr" rid="bibr39-1759720X13480280">Dooley <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr62-1759720X13480280">Houssiau <italic>et al</italic>. 2010</xref>].</p>
<p>The two sets of guidelines have also highlighted other aspects of good practice such as the initial use of three intravenous methylprednisolone pulses and good control of hypertension (e.g. with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers) and other cardiovascular risk factors.</p>
<p>Other important issues to pay close attention to include adjunctive use of hydroxychloroquine and statin therapy if appropriate; the use of aspirin/anticoagulation when there is a thrombosis risk; annual and other immunization with nonlive vaccines; consideration of annual measurement of immunoglobulins; the use of bone protection agents, particularly in patients on corticosteroids; appropriate sun protection and annual cervical smear tests for female patients. Vitamin D supplementation may also reduce disease activity in SLE [<xref ref-type="bibr" rid="bibr11-1759720X13480280">Bello <italic>et al</italic>. 2012</xref>].</p>
</sec>
<sec id="section3-1759720X13480280">
<title>Belimumab</title>
<p>It has been known for over 10 years that high levels of circulating B-lymphocyte stimulator (BlyS also known as B-cell activating factor or BAFF) are seen in patients with SLE and correlate with immunoglobulin G (IgG) levels, suggesting that inhibition of BlyS could be therapeutic [<xref ref-type="bibr" rid="bibr26-1759720X13480280">Cheema <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr148-1759720X13480280">Zhang <italic>et al.</italic> 2001</xref>].</p>
<p>Belimumab is a human IgG1 lambda monoclonal antibody that binds soluble BlyS and inhibits its function. There have been two large-scale phase III studies of belimumab in SLE; the BLISS-52 and BLISS-76 studies [<xref ref-type="bibr" rid="bibr83-1759720X13480280">Manzi <italic>et al.</italic> 2012</xref>]. In BLISS-52, 865 patients with active SLE were treated with standard care along with 10 mg/kg belimumab, 1 mg/kg intravenous belimumab or placebo at 0, 14 and 28 days and then every 28 days until week 48 with review at week 52. More patients in the belimumab groups achieved an SLE Responder Index (SRI) response than in the placebo group. For belimumab 1 mg/kg the number of responders was 148/288 (51%) [odds ratio (OR) 1.55; 95% confidence interval (CI) 1.10–2.19; <italic>p</italic> = 0.0129], for the 10 mg/kg dose 167/290 (58%) (OR 1.83; 95% CI 1.30–2.59; <italic>p</italic> = 0.0006) and for placebo 125/287 (44%) at week 52 [<xref ref-type="bibr" rid="bibr96-1759720X13480280">Navarra <italic>et al.</italic> 2011</xref>]. Belimumab at both doses was well tolerated, it reduced the flare rate, improved serologic markers in patients with serologically active disease and reduced corticosteroid use. Adverse events were similar to those of the placebo group. In BLISS-76 a similar trial design in 819 patients generated SRI response rates for belimumab 1 mg/kg, 10 mg/kg and placebo at 52 weeks of 40.6%, 43.2% and 33.5% (<italic>p</italic> = 0.017 for 10 mg/kg <italic>versus</italic> placebo and <italic>p</italic> = 0.089 for 1 mg/kg <italic>versus</italic> placebo). Again the rate of flares was less in the belimumab groups with no increase in adverse event rate [<xref ref-type="bibr" rid="bibr46-1759720X13480280">Furie <italic>et al.</italic> 2011</xref>]. These studies excluded patients with active lupus nephritis or severe central nervous system involvement. Patients with higher disease activity clinically or serologically had greater benefit [<xref ref-type="bibr" rid="bibr137-1759720X13480280">van Vollenhoven <italic>et al.</italic> 2012</xref>]. The US Food and Drug Administration (FDA) approved belimumab for the therapy of SLE in 2011. Belimumab is also approved in Europe and Canada, although the National Institute for Health and Clinical Excellence in the UK is not currently recommending its use on cost-effectiveness grounds.</p>
</sec>
<sec id="section4-1759720X13480280">
<title>Rituximab</title>
<p>Rituximab is a chimeric monoclonal antibody that depletes CD20+ B cells and has been effective therapy in B-cell non-Hodgkin lymphoma, rheumatoid arthritis and antineutrophil cytoplasmic antibody-positive vasculitis. In the EXPLORER study, of 257 patients with moderately active SLE assessed, 88 received placebo and 169 received 1 g rituximab (1:2 ratio) at week 0, 2, 24 and 26 with evaluation at week 52. Intravenous methylprednisolone 100 mg was given with each infusion. Oral prednisolone was tapered in both groups according to a preset protocol and background therapy with azathioprine, mycophenolate or methotrexate was continued. The study failed to demonstrate benefit for rituximab as additive therapy in this situation [<xref ref-type="bibr" rid="bibr89-1759720X13480280">Merrill <italic>et al.</italic> 2011</xref>].</p>
<p>In the second major trial of rituximab in SLE, the Lupus Nephritis Assessment with rituximab Study (LUNAR), 144 patients with active class III or class IV lupus nephritis were randomized to receive 1 g rituximab (<italic>n</italic> = 72) or placebo (<italic>n</italic> = 72) at weeks 0, 2, 24 and 26 with the primary outcome an assessment of renal status at week 52. Intravenous methylprednisolone 1 g was given prior to the first infusion and within 3 days and a further 100 mg was given prior to the subsequent infusions. Oral prednisolone up to 60 mg was given daily up to day 16 and then tapered. Mycophenolate 1.5 g/day increased up to a maximum of 3 g/day in divided doses was also given. The overall renal response rates were 56.9% in the patients receiving rituximab and 45.8% among those receiving placebo (<italic>p</italic> = 0.18). Eight patients in the placebo group required cyclophosphamide rescue therapy compared with none of the rituximab-treated patients. The rituximab-treated group had a greater reduction in anti-dsDNA antibody levels (<italic>p</italic> = 0.007). Rituximab also had a greater beneficial effect in patients of African-American or Hispanic ethnicity. Nevertheless, as in the EXPLORER study, the primary outcome was not met [<xref ref-type="bibr" rid="bibr111-1759720X13480280">Rovin <italic>et al</italic>. 2012</xref>].</p>
<p>In both the EXPLORER and LUNAR studies, the widely held expert view is that the relatively effective background therapy with corticosteroids obscured the underlying value of rituximab as a nonsteroid therapy for SLE and lupus nephritis and that further studies designed to reflect this will demonstrate this in the future [<xref ref-type="bibr" rid="bibr146-1759720X13480280">Weidenbusch <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr65-1759720X13480280">Isenberg, 2012</xref>; <xref ref-type="bibr" rid="bibr54-1759720X13480280">Gregersen and Jayne, 2012</xref>; <xref ref-type="bibr" rid="bibr102-1759720X13480280">Pepper <italic>et al.</italic> 2009</xref>]. Another consideration is that although the effect size was comparable to that observed in the belimumab studies, the smaller numbers of participants in the rituximab studies made it more difficult to achieve the primary outcomes.</p>
<p>Furthermore, there are some data that regimes for lupus nephritis that include rituximab with pulsed steroids followed by maintenance therapy with MMF and no further steroid use could even replace corticosteroid-based regimes in the future [<xref ref-type="bibr" rid="bibr79-1759720X13480280">Lightstone, 2012</xref>].</p>
</sec>
</sec>
<sec id="section5-1759720X13480280">
<title>Antiphospholipid (Hughes) syndrome</title>
<p>In the antiphospholipid antibody (Hughes) syndrome (APS), antibodies directed against phospholipids lead to an increased risk of arterial and venous thrombosis, recurrent pregnancy loss or other obstetric features [<xref ref-type="bibr" rid="bibr57-1759720X13480280">Harris <italic>et al</italic>. 1986</xref>]. It can occur as a syndrome in its own right or in association with SLE. The antibodies can be detected directly in the form of antiphospholipid/anticardiolipin or anti-ß2 glycoprotein (a cofactor for phospholipids) antibodies by enzyme-linked immunosorbent assay or indirectly through the lupus anticoagulant clotting test typically using the dilute Russell viper’s venom test to demonstrate an <italic>in vitro</italic> (antibody) inhibitor of the clotting system.</p>
<p>Treatment depends on the nature of the clinical and laboratory presentation. In patients with the antibodies but without a history of thrombosis, the risk–benefit analysis for taking low-dose aspirin is unclear [<xref ref-type="bibr" rid="bibr41-1759720X13480280">Erkan <italic>et al.</italic> 2007</xref>]. A positive lupus anticoagulant test is most closely linked with thrombosis risk and adverse obstetric outcome [<xref ref-type="bibr" rid="bibr47-1759720X13480280">Galli <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr80-1759720X13480280">Lockshin <italic>et al.</italic> 2012</xref>] and patients with a positive result for all three antibody tests are at greatest risk [<xref ref-type="bibr" rid="bibr101-1759720X13480280">Pengo <italic>et al.</italic> 2012</xref>]. Anecdotally, clopidogrel might be used in patients who are allergic to aspirin.</p>
<p>Once a patient has had a thrombosis, however, the consensus would be to anticoagulate them for life due to the high risk of further thrombosis [<xref ref-type="bibr" rid="bibr68-1759720X13480280">Khamashta <italic>et al.</italic> 1995</xref>; <xref ref-type="bibr" rid="bibr32-1759720X13480280">Crowther <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr44-1759720X13480280">Finazzi <italic>et al.</italic> 2005</xref>]. Current practice would distinguish between patients with a single venous thrombosis for whom an international normalized ratio (INR) of 2–3 may be sufficient and patients with an arterial thrombosis or recurrent venous thromboses for whom a higher target INR of 3–4 would be more appropriate [<xref ref-type="bibr" rid="bibr114-1759720X13480280">Ruiz-Irastorza <italic>et al</italic>. 2007</xref>].</p>
<p>In patients who are intolerant of, or resistant to, warfarin [<xref ref-type="bibr" rid="bibr119-1759720X13480280">Scoble <italic>et al</italic>. 2011</xref>], low molecular weight heparin (LMWH) can be used [<xref ref-type="bibr" rid="bibr138-1759720X13480280">Vargas-Hitos <italic>et al</italic>. 2011</xref>]. Long-term use of LMWH is associated with osteoporosis and thrombocytopenia.</p>
<p>One recent development is of new oral anticoagulants such as apixaban (a factor Xa inhibitor), dabigatran (a thrombin inhibitor) and rivaroxaban (a factor Xa inhibitor) [<xref ref-type="bibr" rid="bibr48-1759720X13480280">Garcia <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr30-1759720X13480280">Cohen and Machin, 2010</xref>]. They do not require time-intensive monitoring and dose adjustment but they are not easily reversible if bleeding problems arise. There is a planned clinical trial of rivaroxaban in APS funded by Arthritis Research UK that will address equivalence to warfarin in an APS population (<ext-link ext-link-type="uri" xlink:href="http://www.ucl.ac.uk/ctu/researchareas/other/othertrials">http://www.ucl.ac.uk/ctu/researchareas/other/othertrials</ext-link>).</p>
<p>There is no evidence in most ‘straightforward’ cases of APS that immunosuppression with corticosteroids or disease-modifying drugs have any beneficial effect. Hydroxychloroquine does appear to have a beneficial effect on thrombosis risk in APS, at least in patients with SLE [<xref ref-type="bibr" rid="bibr103-1759720X13480280">Petri, 1996</xref>]. Statins also have antithrombotic effects and may be sensible adjunctive therapy [<xref ref-type="bibr" rid="bibr67-1759720X13480280">Jajoria <italic>et al</italic>. 2009</xref>].</p>
<p>The potential exception to this is in rare patients (about 1% of APS cases) with the catastrophic APS in which a diffuse thrombotic microvasculopathy affecting the lungs, brain, heart, kidney, skin and gastrointestinal tract is associated with a high mortality rate of 30–50%. The mortality rate has improved in recent years with the use of full anticoagulation, intravenous steroids, with or without cyclophosphamide, antibiotics for any sepsis and the use of plasma exchange and intravenous immunoglobulins (IVIGs) [<xref ref-type="bibr" rid="bibr25-1759720X13480280">Cervera <italic>et al</italic>. 2009</xref>]. Some recent papers have also described the use of rituximab with beneficial effect in resistant cases [<xref ref-type="bibr" rid="bibr70-1759720X13480280">Khattri <italic>et al</italic>. 2012</xref>] and a clinical trial is also ongoing [ClinicalTrials.gov identifier: NCT00537290].</p>
<p>Warfarin is associated with a high risk of fetal malformation in the first trimester of pregnancy and with fetal bleeding thereafter. The standard of care, therefore, for women with antiphospholipid antibodies and recurrent pregnancy loss is the combination of low-dose aspirin plus prophylactic doses of heparin (unfractionated or low molecular weight) [<xref ref-type="bibr" rid="bibr3-1759720X13480280">American College of Obstetricians and Gynaecologists Committee on Practice Bulletins – Obstetrics, 2011</xref>; <xref ref-type="bibr" rid="bibr40-1759720X13480280">Empson <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr81-1759720X13480280">Mak <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr35-1759720X13480280">Danza <italic>et al.</italic> 2012</xref>]. This has improved the rate of live births very substantially to around 75% in some of the above studies. Some studies have suggested, however, that heparin does not confer additional benefit to aspirin alone [<xref ref-type="bibr" rid="bibr76-1759720X13480280">Laskin <italic>et al</italic>. 2009</xref>], but this is not the current consensus.</p>
<p>The role of prednisolone in improving the outcome of obstetric APS has been controversial. Initial studies using high-dose prednisolone did not identify any benefit and an increased risk of hypertensive complications and diabetes mellitus [<xref ref-type="bibr" rid="bibr75-1759720X13480280">Laskin <italic>et al</italic>. 1997</xref>]. More recent studies of low-dose prednisolone, for example 10 mg/day during the first trimester, have suggested benefit in women with recurrent pregnancy loss in whom conventional approaches have not been effective [<xref ref-type="bibr" rid="bibr19-1759720X13480280">Bramham <italic>et al</italic>. 2011</xref>]. As a result the role of prednisolone is being reevaluated. IVIG is another therapy that can be tried, although evidence for effectiveness is limited.</p>
</sec>
<sec id="section6-1759720X13480280">
<title>Scleroderma</title>
<p>The principle abnormality in scleroderma is of skin and internal organ thickening (fibrosis). The spectrum of the disorder ranges from more localized disease such as the CREST syndrome (Calcinosis, Raynaud’s, oEsophageal dysfunction, Sclerodactyly, Telangiectasia) to widespread skin and internal organ fibrosis. The more serious and potentially life-shortening complications of the disease are pulmonary arterial hypertension (PAH), interstitial lung disease (ILD) and kidney involvement. There are no specific therapies for the disease in general but over the past few years there have been significant improvements in the overall management of each of these more serious components.</p>
<sec id="section7-1759720X13480280">
<title>Pulmonary arterial hypertension</title>
<p>Pulmonary arterial hypertension (PAH) is a major cause of death in scleroderma. Prior to specific therapies the 5-year survival rate of patients with scleroderma and PAH was 10% compared with 80% for patients without PAH [<xref ref-type="bibr" rid="bibr45-1759720X13480280">Fischer <italic>et al</italic>. 2012</xref>]. It is now over 10 years since the key studies of bosentan, an endothelin receptor antagonist, demonstrated improvement in haemodynamic parameters and symptoms in PAH [<xref ref-type="bibr" rid="bibr112-1759720X13480280">Rubin <italic>et al.</italic> 2002</xref>]. Among the FDA-approved therapies it is recommended that calcium channel blockade, bosentan, ambrisentan, sildanefil and tadalafil are used for less severely ill patients while intravenous iloprost, teprostinil and epoprostenol are used for more severely affected patients [<xref ref-type="bibr" rid="bibr143-1759720X13480280">Walker and Pope, 2011</xref>, <xref ref-type="bibr" rid="bibr144-1759720X13480280">2012</xref>].</p>
<p>One key advance in the management of this condition has been the introduction of regular annual or alternate year [in low-risk patients with stable disease &gt;10 years with no dyspnoea, a carbon monoxide diffusing capacity (DLCO) &gt; 70% and a forced vital capacity % (FVC%):DLCO% ratio &lt;1.6] screening with echocardiography and lung function tests to identify early asymptomatic PAH [<xref ref-type="bibr" rid="bibr106-1759720X13480280">Pope <italic>et al</italic>. 2012</xref>]. A disproportionate fall in the DLCO, particularly to less than 50% or a FVC%:DLCO% ratio of over 1.6 is suggestive of PAH rather than ILD. Echocardiographic estimation of pulmonary systolic arterial pressure of over 35–45 mmHg is another indicator of potential PAH requiring confirmation by right heart catheterization.</p>
<p>The DETECT study (<ext-link ext-link-type="uri" xlink:href="http://www.med.umich.edu/scleroderma/pdf/1-DETECT%20ACR%20poster,%20D3%2013%2010%2008%20(5-column).pdf">http://www.med.umich.edu/scleroderma/pdf/1-DETECT%20ACR%20poster,%20D3%2013%2010%2008%20(5-column).pdf</ext-link>) is currently ongoing to further evaluate screening for PAH in scleroderma. Brain natriuretic peptide (BNP) or N-terminal BNP are being studied for their potential as screening tools for PAH but are not sensitive enough for routine clinical use yet [<xref ref-type="bibr" rid="bibr24-1759720X13480280">Cavagna <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr29-1759720X13480280">Chung <italic>et al</italic>. 2010</xref>]. Riociguat, a soluble guanylate cyclase stimulator is a potential therapy of interest in PAH [<xref ref-type="bibr" rid="bibr118-1759720X13480280">Schermuly <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section8-1759720X13480280">
<title>Interstitial lung disease</title>
<p>ILD is another major cause of mortality. There have been two randomized controlled trials of cyclophosphamide in the treatment of scleroderma-associated ILD [<xref ref-type="bibr" rid="bibr63-1759720X13480280">Hoyles <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr132-1759720X13480280">Tashkin <italic>et al.</italic> 2006</xref>]. Tashkin and colleagues evaluated 145 patients with scleroderma and ILD in the USA, randomized to either oral cyclophosphamide up to 2 mg/kg/day or placebo. There was a statistically significant but small beneficial effect at 12 and 24 months in favour of cyclophosphamide on FVC of 2.53% (CI 0.28–4.79%) and some modest effect on symptoms and quality of life. A further study, Scleroderma Lung Study-2 (SLS-2), will compare cyclophosphamide with MMF over 2 years. The second trial [<xref ref-type="bibr" rid="bibr63-1759720X13480280">Hoyles <italic>et al.</italic> 2006</xref>] involved 45 patients in the UK who were randomized to receive either prednisolone and six infusions of cyclophosphamide at monthly intervals followed by maintenance therapy with azathioprine, or to receive placebo formulations of each of these. At 12 months there was no significant difference between the groups, although a trend towards improvement in FVC (<italic>p</italic> = 0.08) and six withdrawals in the placebo group compared with three in the active group. Nevertheless, these trials do not suggest major benefit for a potentially toxic therapy. A meta-analysis of 69 patients in the literature who received MMF demonstrated similar results [<xref ref-type="bibr" rid="bibr135-1759720X13480280">Tzouvelekis <italic>et al.</italic> 2012</xref>].</p>
<p>In the absence of highly effective therapy one recent approach has been to try and stratify patients with more extensive disease for whom intensive therapy might be more likely to be worthwhile [<xref ref-type="bibr" rid="bibr51-1759720X13480280">Goh <italic>et al.</italic> 2008</xref>]. Goh and colleagues reviewed a cohort of 215 patients with scleroderma ILD for whom high-resolution computed tomography (HRCT) and pulmonary function tests (PFT) data were available. A total of 75 (35%) died. An HRCT with over 20% lung involvement by ILD (ground glass or reticulation) was identified as a threshold for increased mortality. Patients with lung disease of less than 20% were classified as having limited ILD with a better prognosis and those with over 20% as having extensive ILD with a worse prognosis. In those patients whose HRCT could not be clearly classified in this way, the FVC was utilized such that those with an FVC of at least 70% were classified into the limited ILD group and those with an FVC less than 70% were classified as having more extensive disease. The logic of this approach is that systemic sclerosis (SSc)-associated ILD often corresponds to nonspecific interstitial pneumonia (inflammation &gt; fibrosis) rather than the usual interstitial pneumonia (fibrosis &gt; inflammation) in the majority of cases [<xref ref-type="bibr" rid="bibr94-1759720X13480280">Mouthon <italic>et al</italic>. 2007</xref>] and therefore individuals with more extensive ILD would receive cyclophosphamide therapy whereas MMF therapy may be more appropriate for patients with limited scleroderma-related ILD. Although they are only present in a small number of patients (around 3%) the presence of antibodies against the U11/U12 RNP complex may indicate ILD in patients with scleroderma [<xref ref-type="bibr" rid="bibr43-1759720X13480280">Fertig <italic>et al</italic>. 2009</xref>].</p>
<p>It is also important to remember simple treatable contributors to lung pathology, such as reflux disease as well as optimizing other general health issues such as good nutrition [<xref ref-type="bibr" rid="bibr7-1759720X13480280">Baron <italic>et al</italic>. 2009</xref>] and treating causes of iron deficiency anaemia, for example due to gastric antral vascular ectasia [<xref ref-type="bibr" rid="bibr64-1759720X13480280">Ingraham <italic>et al</italic>. 2010</xref>]. Development of a cough can be due to dryness (secondary Sjögren’s syndrome), fibrosis, laryngeal or gastro-oesophageal reflux or more serious general pathology (e.g. lung cancer) [<xref ref-type="bibr" rid="bibr31-1759720X13480280">Colaci <italic>et al</italic>. 2013</xref>].</p>
</sec>
<sec id="section9-1759720X13480280">
<title>Renal crisis</title>
<p>Scleroderma renal crisis describes the development of new and severe hypertension in association with renal failure in patients with scleroderma. It is usually but not exclusively associated with diffuse disease and patients with anti-RNA polymerase antibodies [<xref ref-type="bibr" rid="bibr38-1759720X13480280">Denton <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr69-1759720X13480280">Khanna and Denton, 2010</xref>]. Prior to the introduction of ACE inhibition the outcome was poor. Even so, the renal outcome is variable with the best outlook occurring if it is treated early and aggressively [<xref ref-type="bibr" rid="bibr10-1759720X13480280">Batal <italic>et al.</italic> 2009</xref>, <xref ref-type="bibr" rid="bibr9-1759720X13480280">2010</xref>]. Management involves strict monitoring, tight control of blood pressure, inpatient management with intravenous prostacyclin in the event of microangiopathic haemolytic anaemia or hypertensive retinopathy.</p>
</sec>
<sec id="section10-1759720X13480280">
<title>Digital ulceration and Raynaud’s</title>
<p>Severe Raynaud’s phenomenon, particularly with digital ulceration, is a major clinical problem in SSc. Calcium channel blockers are typically used as effective first-line medical therapy. ACE inhibition was commonly used second line until clinical trials demonstrated that although this may be effective therapy in scleroderma renal crisis it has little or no benefit in preventing digital ulceration [<xref ref-type="bibr" rid="bibr50-1759720X13480280">Gliddon <italic>et al.</italic> 2007</xref>]. α Blockers, angiotensin receptor inhibitors (e.g. losartan), serotonin uptake inhibitors (fluoxetine), moxisylyte and other oral therapies may be worth trying in particular patients [<xref ref-type="bibr" rid="bibr58-1759720X13480280">Henness and Wigley, 2007</xref>; <xref ref-type="bibr" rid="bibr127-1759720X13480280">Stewart and Morling, 2012</xref>]. Patients who fail to respond to oral therapy have traditionally been treated with 3–5-day or longer courses of iloprost [<xref ref-type="bibr" rid="bibr58-1759720X13480280">Henness and Wigley, 2007</xref>; <xref ref-type="bibr" rid="bibr143-1759720X13480280">Walker and Pope, 2011</xref>]. Sildenafil has also shown to have potential benefit in small studies [<xref ref-type="bibr" rid="bibr22-1759720X13480280">Brueckner <italic>et al.</italic> 2010</xref>]. Two randomized controlled trials have demonstrated that bosentan reduces the development of new ulcers, although it does not speed healing of existing ulcers [<xref ref-type="bibr" rid="bibr72-1759720X13480280">Korn <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr86-1759720X13480280">Matucci-Cerinic <italic>et al.</italic> 2011</xref>].</p>
</sec>
</sec>
<sec id="section11-1759720X13480280">
<title>Myositis</title>
<p>Polymyositis and dermatomyositis (DM) are the two major forms of idiopathic inflammatory myopathies (IIMs) [<xref ref-type="bibr" rid="bibr91-1759720X13480280">Miller, 2012</xref>]. Inclusion body myositis (IBM) is a third important subgroup of IIM. IBM is associated histologically with fewer inflammatory changes and with the presence of basophilic granular inclusions, rimmed vacuoles and eosinophilic cytoplasmic inclusions. Involvement of the long flexors of the hands and a particularly high risk of falls might suggest IBM. DM has also been linked to malignancy, particularly in older patients [<xref ref-type="bibr" rid="bibr23-1759720X13480280">Callen, 1994</xref>].</p>
<p>Corticosteroids are the usual first-line therapy, for example, prednisolone 1 mg/kg/day initially at least for 4–12 weeks and then tapered after a month by 10–20% of the daily dose monthly to the lowest possible maintenance dose. There are small, randomized trials of conventional disease-modifying antirheumatic drugs, such as methotrexate, azathioprine, ciclosporin, tacrolimus, cyclophosphamide or mycophenolate [<xref ref-type="bibr" rid="bibr52-1759720X13480280">Gordon <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr1-1759720X13480280">Aggarwal and Oddis, 2012</xref>] (<ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/ISRCTN40085050">http://www.controlled-trials.com/ISRCTN40085050</ext-link>), demonstrating only modest effects. IBM is less likely to respond and in a patient who is not responding to immunosuppressant therapy the diagnosis of IBM should be carefully considered, if need be with a second muscle biopsy. Motor neurone disease is another differential to consider.</p>
<p>In patients resistant to corticosteroids, IVIG has been identified as a promising second-line therapy [<xref ref-type="bibr" rid="bibr145-1759720X13480280">Wang <italic>et al</italic>. 2012</xref>]. Dastmalchi and colleagues reported on a 14-week open-label trial with infliximab in 13 refractory patients showing no benefits but more adverse events [<xref ref-type="bibr" rid="bibr36-1759720X13480280">Dastmalchi <italic>et al</italic>. 2008</xref>]. In addition, some biological therapies, particularly rituximab, may have a role, although larger studies are needed [<xref ref-type="bibr" rid="bibr33-1759720X13480280">Dalakas, 2010</xref>]. The Rituximab in Myositis (RIM) study presented in ACR 2011 failed to meet the primary and secondary end points but a large number of patients met the International Myositis Assessment and Clinical Studies Group (IMACS) definition of improvement.</p>
<p>Myositis is associated with long-term disability in 80% of patients and has a standardized mortality ratio three times higher than the general population [<xref ref-type="bibr" rid="bibr84-1759720X13480280">Marie, 2012</xref>]. Screening early and often for ILD in particular with lung function tests and HRCT is advisable.</p>
<p>One of the challenges with rare diseases is the difficulty of validating assessment tools that can be used to assess improvement in clinical trials. International collaborations such as IMACS and the Paediatric Rheumatology International Trials Organisation have been working to develop individual measures and have also proposed preliminary definitions of improvement [<xref ref-type="bibr" rid="bibr110-1759720X13480280">Rider <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr91-1759720X13480280">Miller, 2012</xref>].</p>
<p>In the absence of major therapeutic advances the key recent development in myositis has been the use of novel autoantibodies to classify patients and as potential prognostic indicators (<xref ref-type="table" rid="table1-1759720X13480280">Table 1</xref>).</p>
<table-wrap id="table1-1759720X13480280" position="float">
<label>Table 1.</label>
<caption>
<p>Autoantibodies in myositis.</p>
</caption>
<graphic alternate-form-of="table1-1759720X13480280" xlink:href="10.1177_1759720X13480280-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Antibody and references</th>
<th align="left">Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antisynthetase antibodies [<xref ref-type="bibr" rid="bibr14-1759720X13480280">Betteridge <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr73-1759720X13480280">Labirua-Iturburu <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr87-1759720X13480280">Mehndiratta <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr128-1759720X13480280">Suber <italic>et al.</italic> 2008</xref>]</td>
<td>Anti-(tRNA) synthetase antibodies (ASAs) such as Jo-1 are identified in the blood of about 20% of patients with myositis and have been known about for some time. Over recent years a number of other ASAs have also been identified. These include antibodies against PL7, PL12, OJ, EJ, KS, Ha, Zo</td>
</tr>
<tr>
<td>Anti-Mi2 antibodies [<xref ref-type="bibr" rid="bibr131-1759720X13480280">Targoff and Reichlin, 1985</xref>]</td>
<td>These have been described over 25 years ago and have been linked with classic dermatomyositis rashes. There may be a link with ultraviolet irradiation in their development</td>
</tr>
<tr>
<td>Anti-p155/140 (TIF1-γ) [<xref ref-type="bibr" rid="bibr134-1759720X13480280">Trallero-Araguás <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr95-1759720X13480280">Muro <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr116-1759720X13480280">Saroh <italic>et al.</italic> 2012</xref>]</td>
<td>These antibodies were first described in 2006/2007. They are linked with cancer-associated myositis. In a systematic review of six studies that included 312 adult patients with dermatomyositis the overall sensitivity for malignancy was 78% (95% CI 45–94%) and specificity was 89% (95% CI 82–93%). The OR was 27.26 (95% CI 6.59–112.82). Patients with these antibodies may need particularly careful evaluation for occult malignancy</td>
</tr>
<tr>
<td>Anti-CADM-140/MDA5 [<xref ref-type="bibr" rid="bibr117-1759720X13480280">Sato <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr71-1759720X13480280">Koga <italic>et al.</italic> 2012</xref>]</td>
<td>These antibodies were described in 2005 in Japanese patients with CADM. They are associated with rapidly progressive ILD in Asian cohorts but are less commonly seen in European or North American Caucasian patient cohorts. The anti-CADM antigen has been identified as MDA5, melanoma differentiation gene 5 antibody, and may identify patients with a higher mortality risk</td>
</tr>
<tr>
<td>Anti-NXP-2 (anti-MJ/anti-p140) [<xref ref-type="bibr" rid="bibr55-1759720X13480280">Gunawardena <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr42-1759720X13480280">Espada <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr73-1759720X13480280">Labirua-Itarburu <italic>et al.</italic> 2012</xref>]</td>
<td>This antibody has been principally identified in patients with JDM by several groups. Initially termed MJ and identified as targeting a p140 antigen identified as nuclear matrix protein 2 (NXP2) and found in 23% of patients with JDM in the UK JDM cohort and 25% of ch Associations include calcinosis and muscle contractures. In the EuMyoNet cohort of adult patients 5% of patients appeared to have this antibody although with different clinical associations</td>
</tr>
<tr>
<td>Anti-SAE [<xref ref-type="bibr" rid="bibr13-1759720X13480280">Betteridge <italic>et al.</italic> 2009</xref>]</td>
<td>Anti small ubiquitin-like modifier activating enzyme 1 and 2 (anti-SAE) antibodies have been described in 8% of adult patients with DM in the Adult Onset Myositis Immunogenetic Collaboration (AOMIC UK) study. Clinical associations are with skin manifestations and dysphagia and a lower frequency of malignancy and ILD. There are strong HLA-DRB1*04 associations</td>
</tr>
<tr>
<td>Anti-SRP [<xref ref-type="bibr" rid="bibr129-1759720X13480280">Suzuki <italic>et al</italic> 2012</xref>]</td>
<td>Anti-signal recognition peptide antibodies (SRP) have been identified since the mid 1980s. They are found in about 5% of adult patients with DM and are associated with a necrotizing myopathy that may not respond well to therapy and has a poor neuromuscular outcome</td>
</tr>
<tr>
<td>Anti-200/100 [<xref ref-type="bibr" rid="bibr28-1759720X13480280">Christopher-Stine <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr82-1759720X13480280">Mammen <italic>et al.</italic> 2011</xref>]</td>
<td>Antibodies to this protein complex were described in 2010 in 38 out of 225 patients with myositis. Muscle necrosis was a common finding on biopsy and 63% of patients with this antibody had a history of taking statins. The same group has subsequently identified the target as 3-hydroxy-3-methylglutaryl-coenzyme A reductase protein which is upregulated in muscle by statins</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1759720X13480280">
<p>CADM, clinically amyopathic dermatomyositis; CI, confidence interval; DM, dermatomyositis; ILD, interstitial lung disease; JDM, juvenile dermatomyositis; OR, odds ratio.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-1759720X13480280">
<title>Primary Sjögren’s syndrome</title>
<p>In primary Sjögren’s syndrome (PSS), focal lymphocytic inflammation of exocrine glands is associated with clinical features of glandular dysfunction, particularly of oral and ocular dryness. The immunological features, apart from these histological features, are of anti-Ro with or without anti-La antibodies found in around 70% of patients. Therapy has been principally symptomatic with a focus on oral and ocular hygiene and topical therapies. Glandular stimulants such as pilocarpine have been shown to be effective in symptomatic improvement in patients with residual glandular function [<xref ref-type="bibr" rid="bibr141-1759720X13480280">Vivino <italic>et al.</italic> 1999</xref>].</p>
<p>For the past 10 years the gold standard classification criteria for PSS has been the American-European Consensus Group criteria [<xref ref-type="bibr" rid="bibr139-1759720X13480280">Vitali <italic>et al.</italic> 2002</xref>]. Recently, alternative classification criteria, the preliminary ACR criteria, have been proposed [<xref ref-type="bibr" rid="bibr125-1759720X13480280">Shiboski <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr147-1759720X13480280">Whitcher <italic>et al.</italic> 2010</xref>]. Neither set of criteria include salivary gland ultrasound. In clinical practice, the presence of hypoechoic areas and other features on ultrasound are frequently seen in PSS [<xref ref-type="bibr" rid="bibr130-1759720X13480280">Takagi <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr90-1759720X13480280">Milic <italic>et al</italic>. 2012</xref>]. Magnetic resonance imaging may yield similar results [<xref ref-type="bibr" rid="bibr109-1759720X13480280">Regier <italic>et al</italic>. 2009</xref>].</p>
<p>In order to reach the point at which biological therapies can be studied in PSS there has been considerable development over the past decade of patient-related outcome measures such as the Profile of Fatigue – Sjögren’s International Collaborative Clinical Alliance (SICCA) Symptoms Inventory [<xref ref-type="bibr" rid="bibr17-1759720X13480280">Bowman <italic>et al</italic>. 2009</xref>] and more recently the EULAR Sjögren’s Patient Reported Index [<xref ref-type="bibr" rid="bibr123-1759720X13480280">Seror <italic>et al</italic>. 2011</xref>]; and disease activity measures such as the Sjögren’s Clinical Activity Index [<xref ref-type="bibr" rid="bibr18-1759720X13480280">Bowman <italic>et al.</italic> 2007</xref>] and Sjögren’s Syndrome Disease Activity Index [<xref ref-type="bibr" rid="bibr140-1759720X13480280">Vitali <italic>et al</italic>. 2007</xref>]. More recently, a collaboration, the EULAR Sjögren’s working group, has developed the EULAR Sjögren’s Syndrome Disease Activity Index [<xref ref-type="bibr" rid="bibr121-1759720X13480280">Seror <italic>et al</italic>. 2010a</xref>, <xref ref-type="bibr" rid="bibr122-1759720X13480280">2010b</xref>]. Damage measures have also been developed [<xref ref-type="bibr" rid="bibr140-1759720X13480280">Vitali <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr8-1759720X13480280">Barry <italic>et al</italic>. 2008</xref>]. Other collaborations include the UK Primary Sjögren’s Syndrome Registry, which has been set up to facilitate clinical and basic science research into Sjögren’s syndrome [<xref ref-type="bibr" rid="bibr98-1759720X13480280">Ng <italic>et al.</italic> 2011</xref>]. The SICCA group in the USA has proposed the above alternative criteria sets as well as establishing the SICCA Registry as a repository of clinical and biological samples [<xref ref-type="bibr" rid="bibr34-1759720X13480280">Daniels <italic>et al</italic>. 2009</xref>].</p>
<p>Generally, the prognosis for PSS is good unless patients develop lymphoma when it is more variable [<xref ref-type="bibr" rid="bibr142-1759720X13480280">Voulgarelis <italic>et al.</italic> 2012</xref>]. Although rituximab has not yet been established as routine therapy for PSS, it is now standard practice to incorporate it in regimes, for example, with CHOP Rituximab-cyclophosphamide, Hydroxydaunorubicin, Oncovin (Vincristine), Prednisolone (R-CHOP) for salivary gland lymphoma. A paper by  Theander and colleagues demonstrated that salivary gland biopsy at diagnosis provided important data on long-term lymphoma risk depending on whether B-cell germinal centre (GC) structures were present in the biopsy or not [<xref ref-type="bibr" rid="bibr133-1759720X13480280">Theander <italic>et al</italic>. 2011</xref>]. In a long-term cohort of 175 patients, 6 of 43 patients with GCs on salivary gland biopsy developed lymphoma compared with only 1 of 132 without. The positive predictive value for GC was 16% and the negative predictive value was 99%.</p>
<p>Attempts at using biological therapies have been mixed. Antitumour necrosis factor therapy was ineffective in a double-blind randomized trial [<xref ref-type="bibr" rid="bibr85-1759720X13480280">Mariette <italic>et al.</italic> 2004</xref>]. In the past few years evidence of B-cell and B-cell cytokine involvement, such as BLyS/BAFF, has been of particular interest [<xref ref-type="bibr" rid="bibr66-1759720X13480280">Ittah <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr77-1759720X13480280">Lavie <italic>et al.</italic> 2007</xref>]. A randomized double-blind controlled trial of a single course of rituximab <italic>versus</italic> placebo in France [Tolerance and Efficacy of rituximab in Sjögren’s syndrome (TEARS)] [ClinicalTrials.gov identifier: NCT00740948] failed to meet its primary endpoint but suggested an approximately 10% benefit over placebo (Professor Xavier Mariette, oral presentation at EULAR Congress 2012). A second trial in the UK of two courses of rituximab against placebo funded by Arthritis Research UK is currently ongoing.</p>
<p>There is a theoretical basis for trying other existing biologics such as belimumab (anti-BlyS/BAFF) or tocilizumab (anti-interleukin-6) as well as tackling other biological pathways [<xref ref-type="bibr" rid="bibr97-1759720X13480280">Ng and Bowman, 2011</xref>].</p>
</sec>
<sec id="section13-1759720X13480280">
<title>Basic science</title>
<p>Looking back over the past decade one of the main themes has been the role of B cells and B-cell cytokines in the pathogenesis of many of the autoimmune connective tissue disorders and the use of anti-B-cell/anti-B-cell cytokine agents in their therapy (see above). Looking forwards, a number of themes are emerging, in particular, the potential role of the innate immune system, particularly of type I interferons and toll-like receptors (TLRs) in the triggering and maintenance of these conditions. A second related theme is the insight that high-throughput genome-wide association screening (GWAS), ‘next-generation’ screening and functional genomics will provide into the pathogenesis of these conditions.</p>
<sec id="section14-1759720X13480280">
<title>Innate immunity</title>
<p>TLRs are a group of receptor proteins that recognize structurally conserved molecules shared by many microbial pathogens [<xref ref-type="bibr" rid="bibr92-1759720X13480280">Mills, 2011</xref>]. The name is derived from the Toll gene of <italic>Drosophila</italic>. TLRs are key molecules that alert the immune system to the presence of foreign microorganisms. They can be triggered by a range of bacterial molecules, including lipopolysaccharides, flagella proteins and also some DNA and RNA species. The latter in particular offer a potential mechanism for autoimmunity, since many human autoantigens are either nucleic acids or nucleic acid binding proteins. TLRs then activate a number of signalling pathways, including the activation of type I interferons [<xref ref-type="bibr" rid="bibr15-1759720X13480280">Biggioggero <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr100-1759720X13480280">Pascual <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr126-1759720X13480280">Sozzani <italic>et al</italic>. 2010</xref>].</p>
<p>There has been a substantial amount of work over the past few years exploring the relationships between the innate immune system, TLRs, the type I interferon ‘signature’ [pattern of upregulation of downstream molecules such as the interferon regulatory factor 5 (IRF5) and signal transducer and activator of transcription 4 (STAT4) genes following interferon activation] in SLE [<xref ref-type="bibr" rid="bibr6-1759720X13480280">Banchereau and Pascual, 2006</xref>], PSS [<xref ref-type="bibr" rid="bibr99-1759720X13480280">Nordmark <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr20-1759720X13480280">Brkic <italic>et al</italic>. 2012</xref>], myositis [<xref ref-type="bibr" rid="bibr128-1759720X13480280">Suber <italic>et al</italic>. 2008</xref>] and scleroderma [<xref ref-type="bibr" rid="bibr74-1759720X13480280">Lafyatis and York, 2009</xref>; <xref ref-type="bibr" rid="bibr60-1759720X13480280">Higgs <italic>et al</italic>. 2011</xref>]. Sifalimumab, an anti-interferon antibody, is now being studied in SLE [<xref ref-type="bibr" rid="bibr89-1759720X13480280">Merrill <italic>et al</italic>. 2011</xref>] and potentially could be investigated in other autoimmune diseases over the next few years.</p>
</sec>
<sec id="section15-1759720X13480280">
<title>Genome-wide screening and genomic approaches</title>
<p>In parallel with hypothesis-driven research (e.g. investigating the role of the innate immune system in autoimmune disease), another powerful technique over the past decade has been the use of GWAS to examine the association of common genetic variants with particular diseases. These studies take advantage of several technical developments. The first is the identification of a large number of single-nucleotide polymorphisms (SNPs) covering the entire human genome [<xref ref-type="bibr" rid="bibr124-1759720X13480280">Sherry <italic>et al</italic>. 2001</xref>; <xref ref-type="bibr" rid="bibr49-1759720X13480280">Gibbs <italic>et al</italic>. 2003</xref>]. By demonstrating statistical linkage between the presence of these variants and a particular disease it has been possible to then identify possible genes in the location of the relevant SNPs that could be involved in disease pathogenesis. The second technical development has been of automated ‘chip’ or ‘microarray’ technology that allows millions of SNPs from thousands of individuals to be examined in a short space of time.</p>
<p>A number of GWAS have been performed to date in SLE and scleroderma. They have perhaps been easier to study than some of the rarer connective tissue disorders due to access to large, established cohorts of patients. A number of SNP linkages have been identified in both of these diseases but the human leukocyte antigen region and the regions of the IRF5 and STAT4 genes have emerged as common areas of interest both in SLE [<xref ref-type="bibr" rid="bibr93-1759720X13480280">Moser <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr37-1759720X13480280">Deng and Tsao, 2010</xref>; Sandli<xref ref-type="bibr" rid="bibr98-1759720X13480280">ng <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr108-1759720X13480280">Ramos <italic>et al</italic>. 2011</xref>] and scleroderma [<xref ref-type="bibr" rid="bibr2-1759720X13480280">Allanore <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr53-1759720X13480280">Gorlova <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr107-1759720X13480280">Radstake <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr21-1759720X13480280">Broen <italic>et al</italic>. 2012</xref>], again supporting the potential role of the type I interferon system as important in the pathogenesis of these connective tissue disorders and as a potential target for therapy. Early studies in PSS have demonstrated similar data [<xref ref-type="bibr" rid="bibr78-1759720X13480280">Lessard <italic>et al</italic>. 2011</xref>].</p>
<p>These studies are still at a relatively early stage and it is likely that other potential genes of interest will emerge for hypothesis-driven evaluation over the next decade as will new insights from other next-generation sequencing technologies and functional genomic studies [<xref ref-type="bibr" rid="bibr27-1759720X13480280">Cho and Gregersen, 2011</xref>; <xref ref-type="bibr" rid="bibr120-1759720X13480280">Scofield and Kaufman, 2012</xref>].</p>
</sec>
</sec>
<sec id="section16-1759720X13480280">
<title>Conclusion</title>
<p>The past few years have seen significant changes in clinical practice, for example the increasing use of renal biopsy-driven choices of therapy in lupus nephritis and the introduction of biological therapy in SLE. In scleroderma, closer assessment of patients and the introduction of therapies such as bosentan have improved the outlook for patients with PAH. Challenges still remain, however, particularly to find effective therapies for scleroderma, myositis and Sjögren’s syndrome and to reduce the usage of toxic therapies such as corticosteroids and cyclophosphamide wherever possible. With new oral anticoagulants and a broad range of new biological therapies becoming available, the next few years should also be a period of potentially rapid progress in the therapy of these disorders.</p>
</sec>
</body>
<back>
<ack>
<p>We would like to thank David D’Cruz, Chris Denton, Caroline Gordon, Patrick Gordon Munther Khamashta, Voon Oong and Sonali Wijetilleka for their advice on content.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflicts of interest in preparing this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aggarwal</surname><given-names>R.</given-names></name>
<name><surname>Oddis</surname><given-names>C.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Therapeutic advances in myositis</article-title>. <source>Curr Opin Rheumatol</source> <volume>24</volume>: <fpage>635</fpage>–<lpage>641</lpage>.</citation>
</ref>
<ref id="bibr2-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allanore</surname><given-names>Y.</given-names></name>
<name><surname>Saad</surname><given-names>M.</given-names></name>
<name><surname>Dieude</surname><given-names>P.</given-names></name>
<name><surname>Avouac</surname><given-names>J.</given-names></name>
<name><surname>Distler</surname><given-names>J.</given-names></name>
<name><surname>Amouyel</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis</article-title>. <source>PLoS Genet</source> <volume>7</volume>: <fpage>e1002091</fpage>.</citation>
</ref>
<ref id="bibr3-1759720X13480280">
<citation citation-type="journal">
<collab>American College of Obstetricians and Gynaecologists Committee on Practice Bulletins – Obstetrics</collab> (<year>2011</year>) <article-title>ACOG Practice Bulletin No. 118: Antiphospholipid syndrome</article-title>. <source>Obstet Gynaecol</source> <volume>117</volume>: <fpage>192</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr4-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Appel</surname><given-names>G.</given-names></name>
<name><surname>Contreras</surname><given-names>G.</given-names></name>
<name><surname>Dooley</surname><given-names>M.</given-names></name>
<name><surname>Ginzler</surname><given-names>E.</given-names></name>
<name><surname>Isenberg</surname><given-names>D.</given-names></name>
<name><surname>Jayne</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis</article-title>. <source>Am Soc Nephrol</source> <volume>20</volume>: <fpage>1103</fpage>–<lpage>1112</lpage>.</citation>
</ref>
<ref id="bibr5-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ballou</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>M.</given-names></name>
<name><surname>Kushner</surname><given-names>I.</given-names></name>
</person-group> (<year>1982</year>) <article-title>Clinical features of systemic lupus erythematosus: differences related to race and age of onset</article-title>. <source>Arthritis Rheum</source> <volume>25</volume>: <fpage>55</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr6-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Banchereau</surname><given-names>J.</given-names></name>
<name><surname>Pascual</surname><given-names>V.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Type I interferon in systemic lupus erythematosus and other autoimmune diseases</article-title>. <source>Immunity</source> <volume>25</volume>: <fpage>383</fpage>–<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr7-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baron</surname><given-names>M.</given-names></name>
<name><surname>Hudson</surname><given-names>M.</given-names></name>
<name><surname>Steele</surname><given-names>R.</given-names></name>
</person-group>; <collab>Canadian Scleroderma Research Group</collab> (<year>2009</year>) <article-title>Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database</article-title>. <source>J Rheumatol</source> <volume>36</volume>: <fpage>2737</fpage>–<lpage>2743</lpage>.</citation>
</ref>
<ref id="bibr8-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barry</surname><given-names>R.</given-names></name>
<name><surname>Sutcliffe</surname><given-names>N.</given-names></name>
<name><surname>Isenberg</surname><given-names>D.</given-names></name>
<name><surname>Price</surname><given-names>E.</given-names></name>
<name><surname>Goldblatt</surname><given-names>F.</given-names></name>
<name><surname>Adler</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>The Sjögren’s syndrome damage index: a damage index for use in clinical trials and observational studies in primary Sjögren’s syndrome</article-title>. <source>Rheumatology (Oxford)</source> <volume>47</volume>: <fpage>1193</fpage>–<lpage>1198</lpage>.</citation>
</ref>
<ref id="bibr9-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Batal</surname><given-names>I.</given-names></name>
<name><surname>Domsic</surname><given-names>R.</given-names></name>
<name><surname>Medsger</surname><given-names>T.</given-names></name>
<name><surname>Bastacky</surname><given-names>S.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Scleroderma renal crisis: a pathology perspective</article-title>. <source>Int J Rheumatol</source> <volume>2010</volume>: <fpage>543704</fpage>.</citation>
</ref>
<ref id="bibr10-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Batal</surname><given-names>I.</given-names></name>
<name><surname>Domsic</surname><given-names>R.</given-names></name>
<name><surname>Shafer</surname><given-names>A.</given-names></name>
<name><surname>Medsger</surname><given-names>T.</given-names><suffix>Jr</suffix></name>
<name><surname>Kiss</surname><given-names>L.</given-names></name>
<name><surname>Randhawa</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Renal biopsy findings predicting outcome in scleroderma renal crisis</article-title>. <source>Hum Pathol</source> <volume>40</volume>: <fpage>332</fpage>–<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr11-1759720X13480280">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Bello</surname><given-names>K.J.</given-names></name>
<name><surname>Fang</surname><given-names>H.</given-names></name>
<name><surname>Magder</surname><given-names>L.S.</given-names></name>
<name><surname>Petri</surname><given-names>M</given-names></name>
</person-group> (<year>2012</year>) <article-title>Increase in vitamin D improves disease activity and systolic blood pressure in systemic lupus erythematosus</article-title>. <conf-name>2012 ACR/ARHP Annual Meeting</conf-name>, <conf-loc>Washington, DC</conf-loc>, <conf-date>November 2012</conf-date>. Abstract 1710.</citation>
</ref>
<ref id="bibr12-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bertsias</surname><given-names>G.</given-names></name>
<name><surname>Tektonidou</surname><given-names>M.</given-names></name>
<name><surname>Amoura</surname><given-names>Z.</given-names></name>
<name><surname>Aringer</surname><given-names>M.</given-names></name>
<name><surname>Bajema</surname><given-names>I.</given-names></name>
<name><surname>Berden</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis</article-title>. <source>Ann Rheum Dis</source> <volume>71</volume>: <fpage>1771</fpage>–<lpage>1782</lpage>.</citation>
</ref>
<ref id="bibr13-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Betteridge</surname><given-names>Z.</given-names></name>
<name><surname>Gunawardena</surname><given-names>H.</given-names></name>
<name><surname>Chinoy</surname><given-names>H.</given-names></name>
<name><surname>North</surname><given-names>J.</given-names></name>
<name><surname>Ollier</surname><given-names>W.</given-names></name>
<name><surname>Cooper</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis</article-title>. <source>Ann Rheum Dis</source> <volume>68</volume>: <fpage>1621</fpage>–<lpage>1625</lpage>.</citation>
</ref>
<ref id="bibr14-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Betteridge</surname><given-names>Z.</given-names></name>
<name><surname>Gunawardena</surname><given-names>H.</given-names></name>
<name><surname>McHugh</surname><given-names>N.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Novel autoantibodies and clinical phenotypes in adult and juvenile myositis</article-title>. <source>Arthritis Res Ther</source> <volume>13</volume>: <fpage>209</fpage>.</citation>
</ref>
<ref id="bibr15-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Biggioggero</surname><given-names>M.</given-names></name>
<name><surname>Gabbriellini</surname><given-names>L.</given-names></name>
<name><surname>Meroni</surname><given-names>P.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Type I interferon therapy and its role in autoimmunity</article-title>. <source>Autoimmunity</source> <volume>43</volume>: <fpage>248</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr16-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boumpas</surname><given-names>D.</given-names></name>
<name><surname>Austin</surname><given-names>H.</given-names><suffix>3rd</suffix></name>
<name><surname>Vaughn</surname><given-names>E.</given-names></name>
<name><surname>Klippel</surname><given-names>J.</given-names></name>
<name><surname>Steinberg</surname><given-names>A.</given-names></name>
<name><surname>Yarboro</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis</article-title>. <source>Lancet</source> <volume>340</volume>: <fpage>741</fpage>–<lpage>745</lpage>.</citation>
</ref>
<ref id="bibr17-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bowman</surname><given-names>S.</given-names></name>
<name><surname>Hamburger</surname><given-names>J.</given-names></name>
<name><surname>Richards</surname><given-names>A.</given-names></name>
<name><surname>Barry</surname><given-names>R.</given-names></name>
<name><surname>Rauz</surname><given-names>S.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Patient-reported outcomes in primary Sjögren’s syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort – SICCA Symptoms Inventory</article-title>. <source>Rheumatology (Oxford)</source> <volume>48</volume>: <fpage>140</fpage>–<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr18-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bowman</surname><given-names>S.</given-names></name>
<name><surname>Sutcliffe</surname><given-names>N.</given-names></name>
<name><surname>Isenberg</surname><given-names>D.</given-names></name>
<name><surname>Goldblatt</surname><given-names>F.</given-names></name>
<name><surname>Adler</surname><given-names>M.</given-names></name>
<name><surname>Price</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Sjögren’s Systemic Clinical Activity Index (SCAI): a systemic disease activity measure for use in clinical trials in primary Sjögren’s syndrome</article-title>. <source>Rheumatology (Oxford)</source> <volume>46</volume>: <fpage>1845</fpage>–<lpage>1851</lpage>.</citation>
</ref>
<ref id="bibr19-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bramham</surname><given-names>K.</given-names></name>
<name><surname>Thomas</surname><given-names>M.</given-names></name>
<name><surname>Nelson-Piercy</surname><given-names>C.</given-names></name>
<name><surname>Khamashta</surname><given-names>M.</given-names></name>
<name><surname>Hunt</surname><given-names>B.</given-names></name>
</person-group> (<year>2011</year>) <article-title>First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss</article-title>. <source>Blood</source> <volume>117</volume>: <fpage>6948</fpage>–<lpage>6951</lpage>.</citation>
</ref>
<ref id="bibr20-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brkic</surname><given-names>Z.</given-names></name>
<name><surname>Maria</surname><given-names>N.</given-names></name>
<name><surname>Van Helden-Meeuwsen</surname><given-names>C.</given-names></name>
<name><surname>Van De Merwe</surname><given-names>J.</given-names></name>
<name><surname>Van Daele</surname><given-names>P.</given-names></name>
<name><surname>Dalm</surname><given-names>V.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren’s syndrome and association with disease activity and BAFF gene expression</article-title>. <source>Ann Rheum Dis</source> <day>26</day> <month>June</month> (Epub ahead of print).</citation>
</ref>
<ref id="bibr21-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Broen</surname><given-names>J.</given-names></name>
<name><surname>Coenen</surname><given-names>M.</given-names></name>
<name><surname>Radstake</surname><given-names>T.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Genetics of systemic sclerosis: an update</article-title>. <source>Curr Rheumatol Rep</source> <volume>14</volume>: <fpage>11</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr22-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brueckner</surname><given-names>C.</given-names></name>
<name><surname>Becker</surname><given-names>M.</given-names></name>
<name><surname>Kroencke</surname><given-names>T.</given-names></name>
<name><surname>Huscher</surname><given-names>D.</given-names></name>
<name><surname>Scherer</surname><given-names>H.</given-names></name>
<name><surname>Worm</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study</article-title>. <source>Ann Rheum Dis</source> <volume>69</volume>: <fpage>1475</fpage>–<lpage>1478</lpage>.</citation>
</ref>
<ref id="bibr23-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Callen</surname><given-names>J.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis, and inclusion body myositis</article-title>. <source>Rheum Dis Clin North Am</source> <volume>20</volume>: <fpage>943</fpage>–<lpage>953</lpage>.</citation>
</ref>
<ref id="bibr24-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cavagna</surname><given-names>L.</given-names></name>
<name><surname>Caporali</surname><given-names>R.</given-names></name>
<name><surname>Klersy</surname><given-names>C.</given-names></name>
<name><surname>Ghio</surname><given-names>S.</given-names></name>
<name><surname>Albertini</surname><given-names>R.</given-names></name>
<name><surname>Scelsi</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis</article-title>. <source>J Rheumatol</source> <volume>37</volume>: <fpage>2064</fpage>–<lpage>2070</lpage>.</citation>
</ref>
<ref id="bibr25-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cervera</surname><given-names>R.</given-names></name>
<name><surname>Bucciarelli</surname><given-names>S.</given-names></name>
<name><surname>Plasín</surname><given-names>M.</given-names></name>
<name><surname>Gómez-Puerta</surname><given-names>J.</given-names></name>
<name><surname>Plaza</surname><given-names>J.</given-names></name>
<name><surname>Pons-Estel</surname><given-names>G.</given-names></name><etal/>
</person-group>. <collab>Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum On Antiphospholipid Antibodies)</collab> (<year>2009</year>) <article-title>Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the ‘CAPS Registry’</article-title>. <source>J Autoimmun</source> <volume>32</volume>: <fpage>240</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr26-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheema</surname><given-names>G.</given-names></name>
<name><surname>Roschke</surname><given-names>V.</given-names></name>
<name><surname>Hilbert</surname><given-names>D.</given-names></name>
<name><surname>Stohl</surname><given-names>W.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases</article-title>. <source>Arthritis Rheum</source> <volume>44</volume>: <fpage>1313</fpage>–<lpage>1319</lpage>.</citation>
</ref>
<ref id="bibr27-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cho</surname><given-names>J.</given-names></name>
<name><surname>Gregersen</surname><given-names>P.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Genomics and the multifactorial nature of human autoimmune disease</article-title>. <source>N Engl J Med</source> <volume>365</volume>: <fpage>1612</fpage>–<lpage>1623</lpage>.</citation>
</ref>
<ref id="bibr28-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christopher-Stine</surname><given-names>L.</given-names></name>
<name><surname>Casciola-Rosen</surname><given-names>L.</given-names></name>
<name><surname>Hong</surname><given-names>G.</given-names></name>
<name><surname>Chung</surname><given-names>T.</given-names></name>
<name><surname>Corse</surname><given-names>A.</given-names></name>
<name><surname>Mammen</surname><given-names>A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy</article-title>. <source>Arthritis Rheum</source> <volume>62</volume>: <fpage>2757</fpage>–<lpage>2766</lpage>.</citation>
</ref>
<ref id="bibr29-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chung</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Parsons</surname><given-names>L.</given-names></name>
<name><surname>Hassoun</surname><given-names>P.</given-names></name>
<name><surname>McGoon</surname><given-names>M.</given-names></name>
<name><surname>Badesch</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL identifying systemic sclerosis as a unique phenotype</article-title>. <source>Chest</source> <volume>138</volume>: <fpage>1383</fpage>–<lpage>1394</lpage>.</citation>
</ref>
<ref id="bibr30-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>H.</given-names></name>
<name><surname>Machin</surname><given-names>S.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?</article-title> <source>Lupus</source> <volume>19</volume>: <fpage>486</fpage>–<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr31-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colaci</surname><given-names>M.</given-names></name>
<name><surname>Giuggioli</surname><given-names>D.</given-names></name>
<name><surname>Sebastiani</surname><given-names>M.</given-names></name>
<name><surname>Manfredi</surname><given-names>A.</given-names></name>
<name><surname>Vacchi</surname><given-names>C.</given-names></name>
<name><surname>Spagnolo</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2013</year>) <article-title>Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature</article-title>. <source>Autoimmun Rev</source> <volume>12</volume>: <fpage>374</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr32-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crowther</surname><given-names>M.</given-names></name>
<name><surname>Ginsberg</surname><given-names>J.</given-names></name>
<name><surname>Julian</surname><given-names>J.</given-names></name>
<name><surname>Denburg</surname><given-names>J.</given-names></name>
<name><surname>Hirsh</surname><given-names>J.</given-names></name>
<name><surname>Douketis</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome</article-title>. <source>N Engl J Med</source> <volume>349</volume>: <fpage>1133</fpage>–<lpage>1138</lpage>.</citation>
</ref>
<ref id="bibr33-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dalakas</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Immunotherapy of myositis: issues, concerns and future prospects</article-title>. <source>Nat Rev Rheumatol</source> <volume>6</volume>: <fpage>129</fpage>–<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr34-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daniels</surname><given-names>T.</given-names></name>
<name><surname>Criswell</surname><given-names>L.</given-names></name>
<name><surname>Shiboski</surname><given-names>C.</given-names></name>
<name><surname>Shiboski</surname><given-names>S.</given-names></name>
<name><surname>Lanfranchi</surname><given-names>H.</given-names></name>
<name><surname>Dong</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>An early view of the international Sjögren’s syndrome registry</article-title>. <source>Arthritis Rheum</source> <volume>61</volume>: <fpage>711</fpage>–<lpage>714</lpage>.</citation>
</ref>
<ref id="bibr35-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Danza</surname><given-names>A.</given-names></name>
<name><surname>Ruiz-Irastorza</surname><given-names>G.</given-names></name>
<name><surname>Khamashta</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Antiphospholipid syndrome in obstetrics</article-title>. <source>Best Pract Res Clin Obstet Gynaecol</source> <volume>26</volume>: <fpage>65</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr36-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dastmalchi</surname><given-names>M.</given-names></name>
<name><surname>Grundtman</surname><given-names>C.</given-names></name>
<name><surname>Alexanderson</surname><given-names>H.</given-names></name>
<name><surname>Maragani</surname><given-names>C.P.</given-names></name>
<name><surname>Einarsdottir</surname><given-names>H.</given-names></name>
<name><surname>Helmers</surname><given-names>S.B.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies</article-title>. <source>Ann Rheum Dis</source> <volume>67</volume>(<issue>12</issue>): <fpage>1670</fpage>–<lpage>1677</lpage>.</citation>
</ref>
<ref id="bibr37-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deng</surname><given-names>Y.</given-names></name>
<name><surname>Tsao</surname><given-names>B.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Genetic susceptibility to systemic lupus erythematosus in the genomic era</article-title>. <source>Nat Rev Rheumatol</source> <volume>6</volume>: <fpage>683</fpage>–<lpage>692</lpage>.</citation>
</ref>
<ref id="bibr38-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Denton</surname><given-names>C.</given-names></name>
<name><surname>Lapadula</surname><given-names>G.</given-names></name>
<name><surname>Mouthon</surname><given-names>L.</given-names></name>
<name><surname>Müller-Ladner</surname><given-names>U.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Renal complications and scleroderma renal crisis</article-title>. <source>Rheumatology</source> <volume>48</volume>(<supplement>Suppl. 3</supplement>): <fpage>iii32</fpage>–<lpage>iii35</lpage>.</citation>
</ref>
<ref id="bibr39-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dooley</surname><given-names>M.</given-names></name>
<name><surname>Jayne</surname><given-names>D.</given-names></name>
<name><surname>Ginzler</surname><given-names>E.</given-names></name>
<name><surname>Isenberg</surname><given-names>D.</given-names></name>
<name><surname>Olsen</surname><given-names>N.</given-names></name>
<name><surname>Wofsy</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis</article-title>. <source>N Engl J Med</source> <volume>365</volume>: <fpage>1886</fpage>–<lpage>1895</lpage>.</citation>
</ref>
<ref id="bibr40-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Empson</surname><given-names>M.</given-names></name>
<name><surname>Lassere</surname><given-names>M.</given-names></name>
<name><surname>Craig</surname><given-names>J.</given-names></name>
<name><surname>Scott</surname><given-names>J.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant</article-title>. <source>Cochrane Database Syst Rev</source> <volume>18</volume>: CD002859.</citation>
</ref>
<ref id="bibr41-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erkan</surname><given-names>D.</given-names></name>
<name><surname>Harrison</surname><given-names>M.</given-names></name>
<name><surname>Levy</surname><given-names>R.</given-names></name>
<name><surname>Peterson</surname><given-names>M.</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Sammaritano</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals</article-title>. <source>Arthritis Rheum</source> <volume>56</volume>: <fpage>2382</fpage>–<lpage>2391</lpage>.</citation>
</ref>
<ref id="bibr42-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Espada</surname><given-names>G.</given-names></name>
<name><surname>Maldonado Cocco</surname><given-names>J.</given-names></name>
<name><surname>Fertig</surname><given-names>N.</given-names></name>
<name><surname>Oddis</surname><given-names>C.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein</article-title>. <source>J Rheumatol</source> <volume>36</volume>: <fpage>2547</fpage>–<lpage>2551</lpage>.</citation>
</ref>
<ref id="bibr43-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fertig</surname><given-names>N.</given-names></name>
<name><surname>Domsic</surname><given-names>R.</given-names></name>
<name><surname>Rodriguez-Reyna</surname><given-names>T.</given-names></name>
<name><surname>Kuwana</surname><given-names>M.</given-names></name>
<name><surname>Lucas</surname><given-names>M.</given-names></name>
<name><surname>Medsger</surname><given-names>T.</given-names><suffix>Jr</suffix></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis</article-title>. <source>Arthritis Rheum</source> <volume>61</volume>: <fpage>958</fpage>–<lpage>965</lpage>.</citation>
</ref>
<ref id="bibr44-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finazzi</surname><given-names>G.</given-names></name>
<name><surname>Marchioli</surname><given-names>R.</given-names></name>
<name><surname>Brancaccio</surname><given-names>V.</given-names></name>
<name><surname>Schinco</surname><given-names>P.</given-names></name>
<name><surname>Wisloff</surname><given-names>F.</given-names></name>
<name><surname>Musial</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)</article-title>. <source>J Thromb Haemost</source> <volume>3</volume>: <fpage>848</fpage>–<lpage>853</lpage>.</citation>
</ref>
<ref id="bibr45-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>A.</given-names></name>
<name><surname>Bull</surname><given-names>T.</given-names></name>
<name><surname>Steen</surname><given-names>V.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Practical approach to screening for scleroderma-associated pulmonary arterial hypertension</article-title>. <source>Arthritis Care Res</source> <volume>64</volume>: <fpage>303</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr46-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furie</surname><given-names>R.</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Zamani</surname><given-names>O.</given-names></name>
<name><surname>Cervera</surname><given-names>R.</given-names></name>
<name><surname>Wallace</surname><given-names>D.</given-names></name>
<name><surname>Tegzova</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>63</volume>: <fpage>3918</fpage>–<lpage>3930</lpage>.</citation>
</ref>
<ref id="bibr47-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galli</surname><given-names>M.</given-names></name>
<name><surname>Luciani</surname><given-names>D.</given-names></name>
<name><surname>Bertolini</surname><given-names>G.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature</article-title>. <source>Blood</source> <volume>101</volume>: <fpage>1827</fpage>–<lpage>1832</lpage>.</citation>
</ref>
<ref id="bibr48-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>D.</given-names></name>
<name><surname>Libby</surname><given-names>E.</given-names></name>
<name><surname>Crowther</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>The new oral anticoagulants</article-title>. <source>Blood</source> <volume>115</volume>: <fpage>15</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr49-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gibbs</surname><given-names>R.</given-names></name>
<name><surname>Belmont</surname><given-names>J.</given-names></name>
<name><surname>Hardenbol</surname><given-names>P.</given-names></name>
<name><surname>Willis</surname><given-names>T.</given-names></name>
<name><surname>Yu</surname><given-names>F.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>The International HapMap Project</article-title>. <source>Nature</source> <volume>426</volume>: <fpage>789</fpage>–<lpage>796</lpage>.</citation>
</ref>
<ref id="bibr50-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gliddon</surname><given-names>A.</given-names></name>
<name><surname>Doré</surname><given-names>C.</given-names></name>
<name><surname>Black</surname><given-names>C.</given-names></name>
<name><surname>McHugh</surname><given-names>N.</given-names></name>
<name><surname>Moots</surname><given-names>R.</given-names></name>
<name><surname>Denton</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicentre, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril</article-title>. <source>Arthritis Rheum</source> <volume>56</volume>: <fpage>3837</fpage>–<lpage>3846</lpage>.</citation>
</ref>
<ref id="bibr51-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goh</surname><given-names>N.</given-names></name>
<name><surname>Desai</surname><given-names>S.</given-names></name>
<name><surname>Veeraraghavan</surname><given-names>S.</given-names></name>
<name><surname>Hansell</surname><given-names>D.</given-names></name>
<name><surname>Copley</surname><given-names>S.</given-names></name>
<name><surname>Maher</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Interstitial lung disease in systemic sclerosis: a simple staging system</article-title>. <source>Am J Respir Crit Care Med</source>: <volume>177</volume>: <fpage>1248</fpage>–<lpage>1254</lpage>.</citation>
</ref>
<ref id="bibr52-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gordon</surname><given-names>P.</given-names></name>
<name><surname>Winer</surname><given-names>J.</given-names></name>
<name><surname>Hoogendijk</surname><given-names>J.</given-names></name>
<name><surname>Choy</surname><given-names>E.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis</article-title>. <source>Cochrane Database Syst Rev</source> <volume>8</volume>: CD003643.</citation>
</ref>
<ref id="bibr53-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorlova</surname><given-names>O.</given-names></name>
<name><surname>Martin</surname><given-names>J.</given-names></name>
<name><surname>Rueda</surname><given-names>B.</given-names></name>
<name><surname>Koeleman</surname><given-names>B.</given-names></name>
<name><surname>Ying</surname><given-names>J.</given-names></name>
<name><surname>Teruel</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy</article-title>. <source>PLoS Genet</source> <volume>7</volume>: <fpage>e1002178</fpage>.</citation>
</ref>
<ref id="bibr54-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gregersen</surname><given-names>J.</given-names></name>
<name><surname>Jayne</surname><given-names>D.</given-names></name>
</person-group> (<year>2012</year>) <article-title>B-cell depletion in the treatment of lupus nephritis</article-title>. <source>Nat Rev Nephrol</source> <volume>8</volume>: <fpage>505</fpage>–<lpage>514</lpage>.</citation>
</ref>
<ref id="bibr55-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gunawardena</surname><given-names>H.</given-names></name>
<name><surname>Wedderburn</surname><given-names>L.</given-names></name>
<name><surname>Chinoy</surname><given-names>H.</given-names></name>
<name><surname>Betteridge</surname><given-names>Z.</given-names></name>
<name><surname>North</surname><given-names>J.</given-names></name>
<name><surname>Ollier</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis</article-title>. <source>Arthritis Rheum</source> <volume>60</volume>: <fpage>1807</fpage>–<lpage>1814</lpage>.</citation>
</ref>
<ref id="bibr56-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hahn</surname><given-names>B.</given-names></name>
<name><surname>McMahon</surname><given-names>M.</given-names></name>
<name><surname>Wilkinson</surname><given-names>A.</given-names></name>
<name><surname>Wallace</surname><given-names>W.</given-names></name>
<name><surname>Daikh</surname><given-names>D.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>American College of Rheumatology guidelines for screening, treatment and management of lupus nephritis</article-title>. <source>Arthritis Care Res</source> <volume>64</volume>: <fpage>797</fpage>–<lpage>808</lpage>.</citation>
</ref>
<ref id="bibr57-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harris</surname><given-names>E.</given-names></name>
<name><surname>Chan</surname><given-names>J.</given-names></name>
<name><surname>Asherson</surname><given-names>R.</given-names></name>
<name><surname>Aber</surname><given-names>V.</given-names></name>
<name><surname>Gharavi</surname><given-names>A.</given-names></name>
<name><surname>Hughes</surname><given-names>G.</given-names></name>
</person-group> (<year>1986</year>) <article-title>Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test</article-title>. <source>Arch Intern Med</source> <volume>146</volume>: <fpage>2153</fpage>–<lpage>2156</lpage>.</citation>
</ref>
<ref id="bibr58-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henness</surname><given-names>S.</given-names></name>
<name><surname>Wigley</surname><given-names>F.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Current drug therapy for scleroderma and secondary Raynaud’s phenomenon: evidence-based review</article-title>. <source>Curr Opin Rheumatol</source> <volume>19</volume>: <fpage>611</fpage>–<lpage>618</lpage>.</citation>
</ref>
<ref id="bibr59-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hickman</surname><given-names>R.</given-names></name>
<name><surname>Gordon</surname><given-names>C.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Causes and management of infertility in systemic lupus erythematosus</article-title>. <source>Rheumatology</source> <volume>50</volume>: <fpage>1551</fpage>–<lpage>1558</lpage>.</citation>
</ref>
<ref id="bibr60-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higgs</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>White</surname><given-names>B.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
<name><surname>White</surname><given-names>W.</given-names></name>
<name><surname>Morehouse</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>: <fpage>2029</fpage>–<lpage>2036</lpage>.</citation>
</ref>
<ref id="bibr61-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Houssiau</surname><given-names>F.</given-names></name>
<name><surname>Vasconcelos</surname><given-names>C.</given-names></name>
<name><surname>D’Cruz</surname><given-names>D.</given-names></name>
<name><surname>Sebastiani</surname><given-names>G.</given-names></name>
<name><surname>Garrido</surname><given-names>E.</given-names></name>
<name><surname>Danieli</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomised trial of low-dose versus high-dose intravenous cyclophosphamide</article-title>. <source>Arthritis Rheum</source> <volume>46</volume>: <fpage>2121</fpage>–<lpage>2131</lpage>.</citation>
</ref>
<ref id="bibr62-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Houssiau</surname><given-names>F.</given-names></name>
<name><surname>D’Cruz</surname><given-names>D.</given-names></name>
<name><surname>Sangle</surname><given-names>S.</given-names></name>
<name><surname>Remy</surname><given-names>P.</given-names></name>
<name><surname>Vasconcelos</surname><given-names>C.</given-names></name>
<name><surname>Petrovic</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial</article-title>. <source>Ann Rheum Dis</source> <volume>69</volume>: <fpage>2083</fpage>–<lpage>2089</lpage>.</citation>
</ref>
<ref id="bibr63-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoyles</surname><given-names>R.</given-names></name>
<name><surname>Ellis</surname><given-names>R.</given-names></name>
<name><surname>Wellsbury</surname><given-names>J.</given-names></name>
<name><surname>Lees</surname><given-names>B.</given-names></name>
<name><surname>Newlands</surname><given-names>P.</given-names></name>
<name><surname>Goh</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma</article-title>. <source>Arthritis Rheum</source> <volume>54</volume>: <fpage>3962</fpage>–<lpage>3970</lpage>.</citation>
</ref>
<ref id="bibr64-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ingraham</surname><given-names>K.</given-names></name>
<name><surname>O’Brien</surname><given-names>M.</given-names></name>
<name><surname>Shenin</surname><given-names>M.</given-names></name>
<name><surname>Derk</surname><given-names>C.</given-names></name>
<name><surname>Steen</surname><given-names>V.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors</article-title>. <source>J Rheumatol</source> <volume>37</volume>: <fpage>603</fpage>–<lpage>607</lpage>.</citation>
</ref>
<ref id="bibr65-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isenberg</surname><given-names>D.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Rituximab – it was the best of times, it was the worst of times</article-title>. <source>Autoimmun Rev</source> <volume>11</volume>: <fpage>790</fpage>–<lpage>791</lpage>.</citation>
</ref>
<ref id="bibr66-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ittah</surname><given-names>M.</given-names></name>
<name><surname>Miceli-Richard</surname><given-names>C.</given-names></name>
<name><surname>Gottenberg</surname><given-names>J.</given-names></name>
<name><surname>Lavie</surname><given-names>F.</given-names></name>
<name><surname>Lazure</surname><given-names>T.</given-names></name>
<name><surname>Ba</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>B cell-activating factor of the tumour necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren’s syndrome</article-title>. <source>Arthritis Res Ther</source> <volume>8</volume>: <fpage>R51</fpage>.</citation>
</ref>
<ref id="bibr67-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jajoria</surname><given-names>P.</given-names></name>
<name><surname>Murthy</surname><given-names>V.</given-names></name>
<name><surname>Papalardo</surname><given-names>E.</given-names></name>
<name><surname>Romay-Penabad</surname><given-names>Z.</given-names></name>
<name><surname>Gleason</surname><given-names>C.</given-names></name>
<name><surname>Pierangeli</surname><given-names>S.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Statins for the treatment of antiphospholipid syndrome?</article-title> <source>Ann N Y Acad Sci</source> <volume>1173</volume>: <fpage>736</fpage>–<lpage>745</lpage>.</citation>
</ref>
<ref id="bibr68-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khamashta</surname><given-names>M.</given-names></name>
<name><surname>Cuadrado</surname><given-names>M.</given-names></name>
<name><surname>Mujic</surname><given-names>F.</given-names></name>
<name><surname>Taub</surname><given-names>N.</given-names></name>
<name><surname>Hunt</surname><given-names>B.</given-names></name>
<name><surname>Hughes</surname><given-names>G.</given-names></name>
</person-group> (<year>1995</year>) <article-title>The management of thrombosis in the antiphosphlipid-antibody syndrome</article-title>. <source>N Engl J Med</source> <volume>332</volume>: <fpage>993</fpage>–<lpage>997</lpage>.</citation>
</ref>
<ref id="bibr69-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khanna</surname><given-names>D.</given-names></name>
<name><surname>Denton</surname><given-names>C.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Evidence-based management of rapidly progressing systemic sclerosis</article-title>. <source>Best Pract Res Clin Rheumatol</source> <volume>24</volume>: <fpage>387</fpage>–<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr70-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khattri</surname><given-names>S.</given-names></name>
<name><surname>Zandman-Goddard</surname><given-names>G.</given-names></name>
<name><surname>Peeva</surname><given-names>E.</given-names></name>
</person-group> (<year>2012</year>) <article-title>B-cell directed therapies in antiphospholipid antibody syndrome – New directions based on murine and human data</article-title>. <source>Autoimmun Rev</source> <volume>11</volume>: <fpage>717</fpage>–<lpage>722</lpage>.</citation>
</ref>
<ref id="bibr71-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koga</surname><given-names>T.</given-names></name>
<name><surname>Fujikawa</surname><given-names>K.</given-names></name>
<name><surname>Horai</surname><given-names>Y.</given-names></name>
<name><surname>Okada</surname><given-names>A.</given-names></name>
<name><surname>Kawashiri</surname><given-names>S.</given-names></name>
<name><surname>Iwamoto</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM</article-title>. <source>Rheumatology</source> <volume>51</volume>: <fpage>1278</fpage>–<lpage>1284</lpage>.</citation>
</ref>
<ref id="bibr72-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Korn</surname><given-names>J.</given-names></name>
<name><surname>Mayes</surname><given-names>M.</given-names></name>
<name><surname>Matucci-Cerinic</surname><given-names>M.</given-names></name>
<name><surname>Rainisio</surname><given-names>M.</given-names></name>
<name><surname>Pope</surname><given-names>J.</given-names></name>
<name><surname>Hachulla</surname><given-names>E.</given-names></name><etal/>
</person-group>. <collab>for the RAPIDS-1 Study Group</collab> (<year>2004</year>) <article-title>Digital ulcers in systemic sclerosis. prevention by treatment with bosentan, an oral endothelin receptor antagonist</article-title>. <source>Arthritis Rheum</source> <volume>50</volume>: <fpage>3985</fpage>–<lpage>3993</lpage>.</citation>
</ref>
<ref id="bibr73-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Labirua-Iturburu</surname><given-names>A.</given-names></name>
<name><surname>Selva-O’Callaghan</surname><given-names>A.</given-names></name>
<name><surname>Vincze</surname><given-names>M.</given-names></name>
<name><surname>Danko</surname><given-names>K.</given-names></name>
<name><surname>Vencovsky</surname><given-names>J.</given-names></name>
<name><surname>Fisher</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature</article-title>. <source>Medicine (Baltimore)</source> <volume>91</volume>: <fpage>206</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr74-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lafyatis</surname><given-names>R.</given-names></name>
<name><surname>York</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Innate immunity and inflammation in systemic sclerosis</article-title>. <source>Curr Opin Rheumatol</source> <volume>21</volume>: <fpage>617</fpage>–<lpage>622</lpage>.</citation>
</ref>
<ref id="bibr75-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laskin</surname><given-names>C.</given-names></name>
<name><surname>Bombardier</surname><given-names>C.</given-names></name>
<name><surname>Hannah</surname><given-names>M.</given-names></name>
<name><surname>Mandel</surname><given-names>F.</given-names></name>
<name><surname>Ritchie</surname><given-names>J.</given-names></name>
<name><surname>Farewell</surname><given-names>V.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss</article-title>. <source>New Eng J Med</source> <volume>337</volume>: <fpage>148</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr76-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laskin</surname><given-names>C.</given-names></name>
<name><surname>Spitzer</surname><given-names>K.</given-names></name>
<name><surname>Clark</surname><given-names>C.</given-names></name>
<name><surname>Crowther</surname><given-names>M.</given-names></name>
<name><surname>Ginsberg</surname><given-names>J.</given-names></name>
<name><surname>Hawker</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial</article-title>. <source>J Rheumatol</source> <volume>36</volume>: <fpage>279</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr77-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lavie</surname><given-names>F.</given-names></name>
<name><surname>Miceli-Richard</surname><given-names>C.</given-names></name>
<name><surname>Ittah</surname><given-names>M.</given-names></name>
<name><surname>Sellam</surname><given-names>J.</given-names></name>
<name><surname>Gottenberg</surname><given-names>J.</given-names></name>
<name><surname>Mariette</surname><given-names>X.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production</article-title>. <source>Ann Rheum Dis</source> <volume>66</volume>: <fpage>700</fpage>–<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr78-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lessard</surname><given-names>C.</given-names></name>
<name><surname>Ice</surname><given-names>J.</given-names></name>
<name><surname>Adrianto</surname><given-names>I.</given-names></name>
<name><surname>Kelly</surname><given-names>J.</given-names></name>
<name><surname>Jonsson</surname><given-names>R.</given-names></name>
<name><surname>Illei</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>A high-density genome-wide association study by the Sjögren’s Genetics Network identifies five novel susceptibility loci for primary Sjögren’s syndrome and confirms association with MHC, IRF5, and BLK</article-title>. <source>Arthritis Rheum</source> <volume>63</volume>: <fpage>S184</fpage>.</citation>
</ref>
<ref id="bibr79-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lightstone</surname><given-names>L.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Lupus nephritis: where are we now?</article-title> <source>Curr Opin Rheumatol</source> <volume>22</volume>: <fpage>252</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr80-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lockshin</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>M.</given-names></name>
<name><surname>Laskin</surname><given-names>C.</given-names></name>
<name><surname>Guerra</surname><given-names>M.</given-names></name>
<name><surname>Branch</surname><given-names>D.</given-names></name>
<name><surname>Merrill</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant but not anticardiolipin antibody in patients with antiphospholipid antibodies</article-title>. <source>Arthritis Rheum</source> <volume>64</volume>: <fpage>2311</fpage>–<lpage>2318</lpage>.</citation>
</ref>
<ref id="bibr81-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mak</surname><given-names>A.</given-names></name>
<name><surname>Cheung</surname><given-names>M.</given-names></name>
<name><surname>Cheak</surname><given-names>A.</given-names></name>
<name><surname>Ho</surname><given-names>R.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression</article-title>. <source>Rheumatology</source> <volume>49</volume>: <fpage>281</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr82-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mammen</surname><given-names>A.</given-names></name>
<name><surname>Chung</surname><given-names>T.</given-names></name>
<name><surname>Christopher-Stine</surname><given-names>L.</given-names></name>
<name><surname>Rosen</surname><given-names>P.</given-names></name>
<name><surname>Rosen</surname><given-names>A.</given-names></name>
<name><surname>Doering</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy</article-title>. <source>Arthritis Rheum</source> <volume>63</volume>: <fpage>713</fpage>–<lpage>721</lpage>.</citation>
</ref>
<ref id="bibr83-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manzi</surname><given-names>S.</given-names></name>
<name><surname>Sanchez-Guerrero</surname><given-names>J.</given-names></name>
<name><surname>Merrill</surname><given-names>J.</given-names></name>
<name><surname>Furie</surname><given-names>R.</given-names></name>
<name><surname>Gladman</surname><given-names>D.</given-names></name>
<name><surname>Navarra</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials</article-title>. <source>Ann Rheum Dis</source> <volume>71</volume>: <fpage>1833</fpage>–<lpage>1838</lpage>.</citation>
</ref>
<ref id="bibr84-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marie</surname><given-names>I.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Morbidity and mortality in adult polymyositis and dermatomyositis</article-title>. <source>Clin Rheumatol Rep</source> <volume>14</volume>: <fpage>275</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr85-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mariette</surname><given-names>X.</given-names></name>
<name><surname>Ravaud</surname><given-names>P.</given-names></name>
<name><surname>Steinfeld</surname><given-names>S.</given-names></name>
<name><surname>Baron</surname><given-names>G.</given-names></name>
<name><surname>Goetz</surname><given-names>J.</given-names></name>
<name><surname>Hachulla</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomised, controlled trial of Remicade in Primary Sjögren’s syndrome (TRIPSS)</article-title>. <source>Arthritis Rheum</source> <volume>50</volume>: <fpage>1270</fpage>–<lpage>1276</lpage>.</citation>
</ref>
<ref id="bibr86-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matucci-Cerinic</surname><given-names>M.</given-names></name>
<name><surname>Denton</surname><given-names>C.</given-names></name>
<name><surname>Furst</surname><given-names>D.</given-names></name>
<name><surname>Mayes</surname><given-names>M.</given-names></name>
<name><surname>Hsu</surname><given-names>V.</given-names></name>
<name><surname>Carpentier</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>: <fpage>32</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr87-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehndiratta</surname><given-names>P.</given-names></name>
<name><surname>Mehta</surname><given-names>S.</given-names></name>
<name><surname>Manjila</surname><given-names>S.</given-names></name>
<name><surname>Kammer</surname><given-names>G.</given-names></name>
<name><surname>Cohen</surname><given-names>M.</given-names></name>
<name><surname>Preston</surname><given-names>D.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Isolated necrotizing myopathy associated with ANTI-PL12 antibody</article-title>. <source>Muscle Nerve</source> <volume>46</volume>: <fpage>282</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr88-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Merrill</surname><given-names>J.</given-names></name>
<name><surname>Neuwelt</surname><given-names>C.</given-names></name>
<name><surname>Wallace</surname><given-names>D.</given-names></name>
<name><surname>Shanahan</surname><given-names>J.</given-names></name>
<name><surname>Latinis</surname><given-names>K.</given-names></name>
<name><surname>Oates</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomised, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial</article-title>. <source>Arthritis Rheum</source> <volume>62</volume>: <fpage>222</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr89-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Merrill</surname><given-names>J.</given-names></name>
<name><surname>Wallace</surname><given-names>D.</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Kirou</surname><given-names>K.</given-names></name>
<name><surname>Yao</surname><given-names>Y.</given-names></name>
<name><surname>White</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>: <fpage>1905</fpage>–<lpage>1913</lpage>.</citation>
</ref>
<ref id="bibr90-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milic</surname><given-names>V.</given-names></name>
<name><surname>Petrovic</surname><given-names>R.</given-names></name>
<name><surname>Boricic</surname><given-names>I.</given-names></name>
<name><surname>Radunovic</surname><given-names>G.</given-names></name>
<name><surname>Marinkovic-Eric</surname><given-names>J.</given-names></name>
<name><surname>Jeremic</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Ultrasonography of major salivary glands could be an alternative tool to sialoscintigraphy in the American-European classification criteria for primary Sjögren’s syndrome</article-title>. <source>Rheumatology (Oxford)</source> <volume>51</volume>: <fpage>1081</fpage>–<lpage>1085</lpage>.</citation>
</ref>
<ref id="bibr91-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>F.</given-names></name>
</person-group> (<year>2012</year>) <article-title>New approaches to the assessment and treatment of the idiopathic inflammatory myopathies</article-title>. <source>Ann Rheum Dis</source> <volume>71</volume>(<supplement>Suppl. 2</supplement>): <fpage>i82</fpage>–<lpage>i85</lpage>.</citation>
</ref>
<ref id="bibr92-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mills</surname><given-names>K.</given-names></name>
</person-group> (<year>2011</year>) <article-title>TLR-dependent T cell activation in autoimmunity</article-title>. <source>Nat Rev Immunol</source> <volume>11</volume>: <fpage>807</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr93-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moser</surname><given-names>K.</given-names></name>
<name><surname>Kelly</surname><given-names>J.</given-names></name>
<name><surname>Lessard</surname><given-names>C.</given-names></name>
<name><surname>Harley</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Recent insights into the genetic basis of systemic lupus erythematosus</article-title>. <source>Genes Immun</source> <volume>10</volume>: <fpage>373</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr94-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mouthon</surname><given-names>L.</given-names></name>
<name><surname>Berezné</surname><given-names>A.</given-names></name>
<name><surname>Brauner</surname><given-names>M.</given-names></name>
<name><surname>Kambouchner</surname><given-names>M.</given-names></name>
<name><surname>Guillevin</surname><given-names>L.</given-names></name>
<name><surname>Valeyre</surname><given-names>D.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Interstitial lung disease in systemic sclerosis</article-title>. <source>Rev Mal Respir</source> <volume>24</volume>: <fpage>1035</fpage>–<lpage>1046</lpage>.</citation>
</ref>
<ref id="bibr95-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muro</surname><given-names>Y.</given-names></name>
<name><surname>Ishikawa</surname><given-names>A.</given-names></name>
<name><surname>Sugiura</surname><given-names>K.</given-names></name>
<name><surname>Akiyama</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies</article-title>. <source>Rheumatology</source> <volume>51</volume>: <fpage>1508</fpage>–<lpage>1513</lpage>.</citation>
</ref>
<ref id="bibr96-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Navarra</surname><given-names>S.</given-names></name>
<name><surname>Guzman</surname><given-names>R.</given-names></name>
<name><surname>Gallacher</surname><given-names>A.</given-names></name>
<name><surname>Hall</surname><given-names>A.</given-names></name>
<name><surname>Levy</surname><given-names>R.</given-names></name>
<name><surname>Jiminez</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised placebo-controlled, phase 3 trial</article-title>. <source>Lancet</source> <volume>377</volume>: <fpage>721</fpage>–<lpage>731</lpage>.</citation>
</ref>
<ref id="bibr97-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>W.</given-names></name>
<name><surname>Bowman</surname><given-names>S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Biological therapies in primary Sjögren’s syndrome</article-title>. <source>Expert Opin Biol Ther</source> <volume>11</volume>: <fpage>921</fpage>–<lpage>936</lpage>.</citation>
</ref>
<ref id="bibr98-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>W.</given-names></name>
<name><surname>Bowman</surname><given-names>S.</given-names></name>
<name><surname>Griffiths</surname><given-names>B</given-names></name>
</person-group>; <collab>UKPSSR Study Group</collab> (<year>2011</year>) <article-title>United Kingdom Primary Sjögren’s syndrome registry: a united effort to tackle an orphan rheumatic disease</article-title>. <source>Rheumatology (Oxford)</source> <volume>50</volume>: <fpage>32</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr99-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nordmark</surname><given-names>G.</given-names></name>
<name><surname>Eloranta</surname><given-names>M.</given-names></name>
<name><surname>Ronnblom</surname><given-names>L.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Primary Sjögren’s syndrome and the type I interferon system</article-title>. <source>Curr Pharm Biotechnol</source> <volume>13</volume>: <fpage>2054</fpage>–<lpage>2062</lpage>.</citation>
</ref>
<ref id="bibr100-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pascual</surname><given-names>V.</given-names></name>
<name><surname>Chaussabel</surname><given-names>D.</given-names></name>
<name><surname>Banchereau</surname><given-names>J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>A genomic approach to human autoimmune diseases</article-title>. <source>Annu Rev Immunol</source> <volume>28</volume>: <fpage>535</fpage>–<lpage>571</lpage>.</citation>
</ref>
<ref id="bibr101-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pengo</surname><given-names>V.</given-names></name>
<name><surname>Ruiz-Irastorza</surname><given-names>G.</given-names></name>
<name><surname>Denas</surname><given-names>G.</given-names></name>
<name><surname>Andreoli</surname><given-names>L.</given-names></name>
<name><surname>Khamashta</surname><given-names>M.</given-names></name>
<name><surname>Tincani</surname><given-names>A.</given-names></name>
</person-group> (<year>2012</year>) <article-title>High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’</article-title>. <source>Autoimmun Rev</source> <volume>11</volume>: <fpage>577</fpage>–<lpage>580</lpage>.</citation>
</ref>
<ref id="bibr102-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pepper</surname><given-names>R.</given-names></name>
<name><surname>Griffith</surname><given-names>M.</given-names></name>
<name><surname>Kirwan</surname><given-names>C.</given-names></name>
<name><surname>Levy</surname><given-names>J.</given-names></name>
<name><surname>Taube</surname><given-names>D.</given-names></name>
<name><surname>Pusey</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Rituximab is an effective therapy for lupus nephritis and allows a reduction in maintenance steroids</article-title>. <source>Nephrol Dial Transplant</source> <volume>24</volume>: <fpage>3717</fpage>–<lpage>3723</lpage>.</citation>
</ref>
<ref id="bibr103-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petri</surname><given-names>M.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective</article-title>. <source>Scand J Rheumatol</source> <volume>25</volume>: <fpage>191</fpage>–<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr104-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Orbai</surname><given-names>A.</given-names></name>
<name><surname>Alarcon</surname><given-names>G.</given-names></name>
<name><surname>Gordon</surname><given-names>C.</given-names></name>
<name><surname>Merrill</surname><given-names>J.</given-names></name>
<name><surname>Fortin</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2012a</year>) <article-title>Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>64</volume>: <fpage>2677</fpage>–<lpage>2686</lpage>.</citation>
</ref>
<ref id="bibr105-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Purvey</surname><given-names>S.</given-names></name>
<name><surname>Fang</surname><given-names>H.</given-names></name>
<name><surname>Magder</surname><given-names>L.</given-names></name>
</person-group> (<year>2012b</year>) <article-title>Predictors of organ damage in systemic lupus erythematosus. The Hopkins Lupus Cohort</article-title>. <source>Arthritis Rheum</source> <volume>64</volume>: <fpage>4021</fpage>–<lpage>4028</lpage>.</citation>
</ref>
<ref id="bibr106-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pope</surname><given-names>J.</given-names></name>
<name><surname>Harding</surname><given-names>S.</given-names></name>
<name><surname>Khimdas</surname><given-names>S.</given-names></name>
<name><surname>Bonner</surname><given-names>A.</given-names></name>
</person-group>; <collab>Canadian Scleroderma Research Group</collab>, <person-group person-group-type="author">
<name><surname>Baron</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group</article-title>. <source>J Rheumatol</source> <volume>39</volume>: <fpage>524</fpage>–<lpage>531</lpage>.</citation>
</ref>
<ref id="bibr107-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Radstake</surname><given-names>T.</given-names></name>
<name><surname>Gorlova</surname><given-names>O.</given-names></name>
<name><surname>Rueda</surname><given-names>B.</given-names></name>
<name><surname>Martin</surname><given-names>J.</given-names></name>
<name><surname>Alizadeh</surname><given-names>B.</given-names></name>
<name><surname>Palomino-Morales</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus</article-title>. <source>Nat Genet</source> <volume>42</volume>: <fpage>426</fpage>–<lpage>429</lpage>.</citation>
</ref>
<ref id="bibr108-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramos</surname><given-names>P.</given-names></name>
<name><surname>Criswell</surname><given-names>L.</given-names></name>
<name><surname>Moser</surname><given-names>K.</given-names></name>
<name><surname>Comeau</surname><given-names>M.</given-names></name>
<name><surname>Williams</surname><given-names>A.</given-names></name>
<name><surname>Pajewski</surname><given-names>N.</given-names></name>
</person-group> (<year>2011</year>) <article-title>A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap</article-title>. <source>PLoS Genet</source> <volume>7</volume>: <fpage>e1002406</fpage>.</citation>
</ref>
<ref id="bibr109-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Regier</surname><given-names>M.</given-names></name>
<name><surname>Ries</surname><given-names>T.</given-names></name>
<name><surname>Arndt</surname><given-names>C.</given-names></name>
<name><surname>Cramer</surname><given-names>M.</given-names></name>
<name><surname>Graessner</surname><given-names>J.</given-names></name>
<name><surname>Reitmeier</surname><given-names>F.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Sjögren’s syndrome of the parotid gland: value of diffusion-weighted echo-planar MRI for diagnosis at an early stage based on MR sialography grading in comparison with healthy volunteers</article-title>. <source>Rofo</source> <volume>181</volume>: <fpage>242</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr110-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rider</surname><given-names>L.</given-names></name>
<name><surname>Werth</surname><given-names>V.</given-names></name>
<name><surname>Huber</surname><given-names>A.</given-names></name>
<name><surname>Alexanderson</surname><given-names>H.</given-names></name>
<name><surname>Rao</surname><given-names>A.</given-names></name>
<name><surname>Ruperto</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Measures of adult and juvenile dermatomyositis, polymyositis and inclusion body myositis</article-title>. <source>Arthritis Care Res</source> <volume>63</volume>: <fpage>S118</fpage>-<lpage>S157</lpage>.</citation>
</ref>
<ref id="bibr111-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rovin</surname><given-names>B.</given-names></name>
<name><surname>Furie</surname><given-names>R.</given-names></name>
<name><surname>Latinis</surname><given-names>K.</given-names></name>
<name><surname>Looney</surname><given-names>R.</given-names></name>
<name><surname>Fervenza</surname><given-names>F.</given-names></name>
<name><surname>Sanchez-Guerrero</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study</article-title>. <source>Arthritis Rheum</source> <volume>64</volume>: <fpage>1215</fpage>–<lpage>1226</lpage>.</citation>
</ref>
<ref id="bibr112-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rubin</surname><given-names>L.</given-names></name>
<name><surname>Badesch</surname><given-names>D.</given-names></name>
<name><surname>Barst</surname><given-names>R.</given-names></name>
<name><surname>Galie</surname><given-names>N.</given-names></name>
<name><surname>Black</surname><given-names>C.</given-names></name>
<name><surname>Keogh</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Bosentan therapy for pulmonary arterial hypertension</article-title>. <source>N Engl J Med</source> <volume>346</volume>: <fpage>896</fpage>–<lpage>903</lpage>.</citation>
</ref>
<ref id="bibr113-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruiz-Irastorza</surname><given-names>G.</given-names></name>
<name><surname>Danza</surname><given-names>A.</given-names></name>
<name><surname>Khamashta</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Glucocorticoid use and abuse in SLE</article-title>. <source>Rheumatology</source> <volume>51</volume>: <fpage>1145</fpage>–<lpage>1153</lpage>.</citation>
</ref>
<ref id="bibr114-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruiz-Irastorza</surname><given-names>G.</given-names></name>
<name><surname>Hunt</surname><given-names>B.</given-names></name>
<name><surname>Khamashta</surname><given-names>M.</given-names></name>
</person-group> (<year>2007</year>) <article-title>A systematic review of secondary thromboprophyllaxis in patients with antiphospholipid antibodies</article-title>. <source>Arthritis Care Res</source> <volume>57</volume>: <fpage>1487</fpage>–<lpage>1495</lpage>.</citation>
</ref>
<ref id="bibr115-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sandling</surname><given-names>J.</given-names></name>
<name><surname>Garnier</surname><given-names>S.</given-names></name>
<name><surname>Sigurdsson</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Nordmark</surname><given-names>G.</given-names></name>
<name><surname>Gunnarsson</surname><given-names>I.</given-names></name>
</person-group> (<year>2011</year>) <article-title>A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE</article-title>. <source>Eur J Hum Genet</source> <volume>19</volume>: <fpage>479</fpage>–<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr116-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saroh</surname><given-names>M.</given-names></name>
<name><surname>Chan</surname><given-names>J.</given-names></name>
<name><surname>Ross</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yamasaki</surname><given-names>Y.</given-names></name>
<name><surname>Yamada</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Autoantibodies to transcription intermediary factor (TIF)1β associated with dermatomyositis</article-title>. <source>Arthritis Res Ther</source> <volume>14</volume>: <fpage>R79</fpage>.</citation>
</ref>
<ref id="bibr117-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sato</surname><given-names>S.</given-names></name>
<name><surname>Kuwana</surname><given-names>M.</given-names></name>
<name><surname>Fujita</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>Y.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease</article-title>. <source>Mod Rheumatol</source> <day>29</day> <month>May</month> (Epub ahead of print).</citation>
</ref>
<ref id="bibr118-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schermuly</surname><given-names>R.</given-names></name>
<name><surname>Janssen</surname><given-names>W.</given-names></name>
<name><surname>Weissmann</surname><given-names>N.</given-names></name>
<name><surname>Stasch</surname><given-names>J.</given-names></name>
<name><surname>Grimminger</surname><given-names>F.</given-names></name>
<name><surname>Ghofrani</surname><given-names>H.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Riociguat for the treatment of pulmonary hypertension</article-title>. <source>Expert Opin Investig Drugs</source> <volume>20</volume>: <fpage>567</fpage>–<lpage>576</lpage>.</citation>
</ref>
<ref id="bibr119-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scoble</surname><given-names>T.</given-names></name>
<name><surname>Wijetilleka</surname><given-names>S.</given-names></name>
<name><surname>Khamashta</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Management of refractory anti-phospholipid syndrome</article-title>. <source>Autoimmun Rev</source> <volume>10</volume>: <fpage>669</fpage>–<lpage>673</lpage>.</citation>
</ref>
<ref id="bibr120-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scofield</surname><given-names>R.</given-names></name>
<name><surname>Kaufman</surname><given-names>K.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Mapping susceptibility gene in systemic lupus erythematosus</article-title>. <source>Methods Mol Biol</source> <volume>900</volume>: <fpage>11</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr121-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seror</surname><given-names>R.</given-names></name>
<name><surname>Mariette</surname><given-names>X.</given-names></name>
<name><surname>Bowman</surname><given-names>S.</given-names></name>
<name><surname>Baron</surname><given-names>G.</given-names></name>
<name><surname>Gottenberg</surname><given-names>J.</given-names></name>
<name><surname>Boostma</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2010a</year>) <article-title>Accurate detection of changes in disease activity in primary Sjögren’s syndrome by the European League Against Rheumatism Sjogren’s Syndrome Disease Activity Index</article-title>. <source>Arthritis Care Res</source> <volume>62</volume>: <fpage>551</fpage>–<lpage>558</lpage>.</citation>
</ref>
<ref id="bibr122-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seror</surname><given-names>R.</given-names></name>
<name><surname>Ravaud</surname><given-names>P.</given-names></name>
<name><surname>Bowman</surname><given-names>S.</given-names></name>
<name><surname>Baron</surname><given-names>G.</given-names></name>
<name><surname>Tzioufas</surname><given-names>A.</given-names></name>
<name><surname>Theander</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2010b</year>) <article-title>EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome</article-title>. <source>Ann Rheum Dis</source> <volume>69</volume>: <fpage>1103</fpage>–<lpage>1109</lpage>.</citation>
</ref>
<ref id="bibr123-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seror</surname><given-names>R.</given-names></name>
<name><surname>Ravaud</surname><given-names>P.</given-names></name>
<name><surname>Mariette</surname><given-names>X.</given-names></name>
<name><surname>Bootsma</surname><given-names>H.</given-names></name>
<name><surname>Theander</surname><given-names>E.</given-names></name>
<name><surname>Hansen</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>EULAR Sjögren’s syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjögren’s syndrome</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>: <fpage>968</fpage>–<lpage>972</lpage>.</citation>
</ref>
<ref id="bibr124-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sherry</surname><given-names>S.</given-names></name>
<name><surname>Ward</surname><given-names>M.</given-names></name>
<name><surname>Kholodov</surname><given-names>M.</given-names></name>
<name><surname>Baker</surname><given-names>J.</given-names></name>
<name><surname>Phan</surname><given-names>L.</given-names></name>
<name><surname>Smigielski</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>dbSNP: the NCBI database of genetic variation</article-title>. <source>Nucleic Acids Res</source> <volume>29</volume>: <fpage>308</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr125-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shiboski</surname><given-names>S.</given-names></name>
<name><surname>Shiboski</surname><given-names>C.</given-names></name>
<name><surname>Criswell</surname><given-names>L.</given-names></name>
<name><surname>Baer</surname><given-names>A.</given-names></name>
<name><surname>Challacombe</surname><given-names>S.</given-names></name>
<name><surname>Lanfranchi</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort</article-title>. <source>Arthritis Care Res</source> <volume>64</volume>: <fpage>475</fpage>–<lpage>487</lpage>.</citation>
</ref>
<ref id="bibr126-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sozzani</surname><given-names>S.</given-names></name>
<name><surname>Bosisio</surname><given-names>D.</given-names></name>
<name><surname>Scarsi</surname><given-names>M.</given-names></name>
<name><surname>Tincani</surname><given-names>A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Type I interferons in systemic autoimmunity</article-title>. <source>Autoimmunity</source> <volume>43</volume>: <fpage>196</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr127-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stewart</surname><given-names>M.</given-names></name>
<name><surname>Morling</surname><given-names>J.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Oral vasodilators for primary Raynaud’s phenomenon</article-title>. <source>Cochrane Database Syst Rev</source> <volume>7</volume>:CD006687.</citation>
</ref>
<ref id="bibr128-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suber</surname><given-names>T.</given-names></name>
<name><surname>Casciola-Rosen</surname><given-names>L.</given-names></name>
<name><surname>Rosen</surname><given-names>A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis</article-title>. <source>Nature Clin Prac Rheumatol</source> <volume>4</volume>: <fpage>201</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr129-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>S.</given-names></name>
<name><surname>Hayashi</surname><given-names>Y.</given-names></name>
<name><surname>Kuwana</surname><given-names>M.</given-names></name>
<name><surname>Tsuburaya</surname><given-names>R.</given-names></name>
<name><surname>Suzuki</surname><given-names>N.</given-names></name>
<name><surname>Nishino</surname><given-names>I.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome</article-title>. <source>Arch Neurol</source> <volume>69</volume>: <fpage>728</fpage>–<lpage>732</lpage>.</citation>
</ref>
<ref id="bibr130-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takagi</surname><given-names>Y.</given-names></name>
<name><surname>Kimura</surname><given-names>Y.</given-names></name>
<name><surname>Nakamura</surname><given-names>H.</given-names></name>
<name><surname>Sasaki</surname><given-names>M.</given-names></name>
<name><surname>Eguchi</surname><given-names>K.</given-names></name>
<name><surname>Nakamura</surname><given-names>T.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Salivary gland ultrasonography: can it be an alternative to sialography as an imaging modality for Sjögren’s syndrome?</article-title> <source>Ann Rheum Dis</source> <volume>69</volume>: <fpage>1321</fpage>–<lpage>1324</lpage>.</citation>
</ref>
<ref id="bibr131-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Targoff</surname><given-names>I.</given-names></name>
<name><surname>Reichlin</surname><given-names>M.</given-names></name>
</person-group> (<year>1985</year>) <article-title>The association between Mi-2 antibodies and dermatomyositis</article-title>. <source>Arthritis Rheum</source> <volume>28</volume>: <fpage>796</fpage>–<lpage>803</lpage>.</citation>
</ref>
<ref id="bibr132-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tashkin</surname><given-names>D.</given-names></name>
<name><surname>Elashoff</surname><given-names>R.</given-names></name>
<name><surname>Clements</surname><given-names>P.</given-names></name>
<name><surname>Goldin</surname><given-names>J.</given-names></name>
<name><surname>Roth</surname><given-names>M.</given-names></name>
<name><surname>Furst</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Cyclophosphamide versus placebo in scleroderma lung disease</article-title>. <source>N Engl J Med</source> <volume>354</volume>: <fpage>2655</fpage>–<lpage>2666</lpage>.</citation>
</ref>
<ref id="bibr133-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Theander</surname><given-names>E.</given-names></name>
<name><surname>Vasaitis</surname><given-names>L.</given-names></name>
<name><surname>Baecklund</surname><given-names>E.</given-names></name>
<name><surname>Nordmark</surname><given-names>G.</given-names></name>
<name><surname>Warfvinge</surname><given-names>G.</given-names></name>
<name><surname>Liedholm</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren’s syndrome</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>(<issue>8</issue>):<fpage>1363</fpage>–<lpage>1368</lpage>.</citation>
</ref>
<ref id="bibr134-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trallero-Araguás</surname><given-names>E.</given-names></name>
<name><surname>Rodrigo-Pendás</surname><given-names>J.</given-names></name>
<name><surname>Selva-O’Callaghan</surname><given-names>A.</given-names></name>
<name><surname>Martínez-Gómez</surname><given-names>X.</given-names></name>
<name><surname>Bosch</surname><given-names>X.</given-names></name>
<name><surname>Labrador-Horrillo</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis</article-title>. <source>Arthritis Rheum</source> <volume>64</volume>: <fpage>523</fpage>–<lpage>532</lpage>.</citation>
</ref>
<ref id="bibr135-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tzouvelekis</surname><given-names>A.</given-names></name>
<name><surname>Galanopoulos</surname><given-names>N.</given-names></name>
<name><surname>Bouros</surname><given-names>E.</given-names></name>
<name><surname>Kolios</surname><given-names>G.</given-names></name>
<name><surname>Zacharis</surname><given-names>G.</given-names></name>
<name><surname>Ntolios</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis</article-title>. <source>Pulm Med</source> <volume>2012</volume>: <fpage>143637</fpage>.</citation>
</ref>
<ref id="bibr136-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urowitz</surname><given-names>M.</given-names></name>
<name><surname>Gladman</surname><given-names>D.</given-names></name>
<name><surname>Tom</surname><given-names>B.</given-names></name>
<name><surname>Ibanez</surname><given-names>D.</given-names></name>
<name><surname>Farewell</surname><given-names>V.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <volume>35</volume>: <fpage>2152</fpage>–<lpage>2158</lpage>.</citation>
</ref>
<ref id="bibr137-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Vollenhoven</surname><given-names>R.</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Cervera</surname><given-names>R.</given-names></name>
<name><surname>Roth</surname><given-names>D.</given-names></name>
<name><surname>Ji</surname><given-names>B.</given-names></name>
<name><surname>Kleoudis</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response</article-title>. <source>Ann Rheum Dis</source> <volume>71</volume>: <fpage>1343</fpage>–<lpage>1349</lpage>.</citation>
</ref>
<ref id="bibr138-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vargas-Hitos</surname><given-names>J.</given-names></name>
<name><surname>Ateka-Barrutia</surname><given-names>O.</given-names></name>
<name><surname>Sangle</surname><given-names>S.</given-names></name>
<name><surname>Khamashta</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Efficacy and safety of long term low molecular weight heparin in patients with antiphospholipid syndrome</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>: <fpage>1652</fpage>–<lpage>1654</lpage>.</citation>
</ref>
<ref id="bibr139-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vitali</surname><given-names>C.</given-names></name>
<name><surname>Bombardieri</surname><given-names>S.</given-names></name>
<name><surname>Jonsson</surname><given-names>R.</given-names></name>
<name><surname>Moutsopoulos</surname><given-names>H.</given-names></name>
<name><surname>Alexander</surname><given-names>E.</given-names></name>
<name><surname>Carsons</surname><given-names>S.</given-names></name><etal/>
</person-group>.; <collab>European Study Group on Classification Criteria for Sjögren’s Syndrome</collab> (<year>2002</year>) <article-title>Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group</article-title>. <source>Ann Rheum Dis</source> <volume>61</volume>: <fpage>554</fpage>–<lpage>558</lpage>.</citation>
</ref>
<ref id="bibr140-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vitali</surname><given-names>C.</given-names></name>
<name><surname>Palombi</surname><given-names>G.</given-names></name>
<name><surname>Baldini</surname><given-names>C.</given-names></name>
<name><surname>Benucci</surname><given-names>M.</given-names></name>
<name><surname>Bombardieri</surname><given-names>S.</given-names></name>
<name><surname>Covelli</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Sjögren’s syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren’s syndrome, derived from an analysis of a cohort of Italian patients</article-title>. <source>Arthritis Rheum</source> <volume>56</volume>: <fpage>2223</fpage>–<lpage>2231</lpage>.</citation>
</ref>
<ref id="bibr141-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vivino</surname><given-names>F.</given-names></name>
<name><surname>Al-Hashimi</surname><given-names>I.</given-names></name>
<name><surname>Khan</surname><given-names>Z.</given-names></name>
<name><surname>LeVeque</surname><given-names>F.</given-names></name>
<name><surname>Salisbury</surname><given-names>P.</given-names><suffix>3rd</suffix></name>
<name><surname>Tran-Johnson</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren’s syndrome: a randomised, placebo-controlled, fixed-dose, multicenter trial. P92–01 Study Group</article-title>. <source>Arch Intern Med</source> <volume>159</volume>: <fpage>174</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr142-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Voulgarelis</surname><given-names>M.</given-names></name>
<name><surname>Ziakas</surname><given-names>P.</given-names></name>
<name><surname>Papageorgiou</surname><given-names>A.</given-names></name>
<name><surname>Baimpa</surname><given-names>E.</given-names></name>
<name><surname>Tzioufas</surname><given-names>A.</given-names></name>
<name><surname>Moutsopoulos</surname><given-names>H.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Prognosis and outcome of non-Hodgkins lymphoma in primary Sjögren’s syndrome</article-title>. <source>Medicine (Baltimore)</source> <volume>91</volume>: <fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr143-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walker</surname><given-names>K.</given-names></name>
<name><surname>Pope</surname><given-names>J.</given-names></name>
</person-group> <collab>for the Scleroderma Clinical Trials Consortium; Canadian Scleroderma Research Group</collab> (<year>2011</year>) <article-title>Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis</article-title>. <source>J Rheumatol</source> <volume>38</volume>: <fpage>1326</fpage>–<lpage>1328</lpage>.</citation>
</ref>
<ref id="bibr144-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walker</surname><given-names>K.</given-names></name>
<name><surname>Pope</surname><given-names>J.</given-names></name>
</person-group>
<collab>for the participating members of the Scleroderma Clinical Trials Consortium (SCTC): Canadian Scleroderma Research Group (CSRG)</collab> (<year>2012</year>) <article-title>Treatment of systemic sclerosis complications: what to use when first-line treatment fails: a consensus of systemic sclerosis experts</article-title>. <source>Semin Arthritis Rheum</source> <volume>42</volume>: <fpage>42</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr145-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Shu</surname><given-names>X.</given-names></name>
<name><surname>Tian</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Zu</surname><given-names>N.</given-names></name>
<name><surname>Ma</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systemic literature review</article-title>. <source>Clin Rheumatol</source> <volume>31</volume>: <fpage>801</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr146-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weidenbusch</surname><given-names>M.</given-names></name>
<name><surname>Rommele</surname><given-names>C.</given-names></name>
<name><surname>Schrottle</surname><given-names>A.</given-names></name>
<name><surname>Anders</surname><given-names>H.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis</article-title>. <source>Nephrol Dial Transplant</source> <volume>28</volume>: <fpage>106</fpage>-<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr147-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whitcher</surname><given-names>J.</given-names></name>
<name><surname>Shiboski</surname><given-names>C.</given-names></name>
<name><surname>Shiboski</surname><given-names>S.</given-names></name>
<name><surname>Heidenreich</surname><given-names>A.</given-names></name>
<name><surname>Kitagawa</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>A simplified quantitative method for assessing keratoconjunctivitis SICCA from the Sjögren’s syndrome international registry</article-title>. <source>Am J Ophthalmol</source> <volume>149</volume>: <fpage>405</fpage>–<lpage>415</lpage>.</citation>
</ref>
<ref id="bibr148-1759720X13480280">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Roschke</surname><given-names>V.</given-names></name>
<name><surname>Baker</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Alarcon</surname><given-names>G.</given-names></name>
<name><surname>Fessler</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus</article-title>. <source>J Immunol</source> <volume>166</volume>: <fpage>6</fpage>–<lpage>10</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>